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Equity and Efficiency Tradeoffs in the Prevention of Heart Disease – Concepts and Evidence 
Gregory H. Cohen 
 
Heart disease, including principally coronary heart disease (CHD) remains the top cause of 
mortality in the United States among adults ages 35 and older. Disparities in CHD mortality 
between socially advantaged and disadvantaged groups, such as whites and blacks have 
persisted for decades. These social gaps persist despite advances in treatments, preventive 
measures, and decreases in population prevalence of smoking that have done much to reduce 
the burden of CHD overall. While these differences in disease burden have been well 
documented, there is a poor understanding of what interventions might narrow these 
differences. An equity-efficiency tradeoffs (EET) framework is a useful lens through which to 
consider this problem. Tradeoffs between equity of intervention efforts and efficiency of the 
returns on such efforts arise when public health interventions are deployed across groups of 
unequal socioeconomic position. While such interventions may achieve overall and intra-group 
improvement, this improvement may come at the expense of stable or widening inter-group 
differences 
 
Aiming to add to this literature, we took three approaches. First, we critically assessed the 
literature in order to identify and summarize prior work on EETs across cardiovascular 
outcomes. We aimed to identify the questions that empirical studies should answer for a given 
 
 
policy, from an EET perspective. Second, recognizing both that tobacco taxation is an effective 
policy intervention on CHD, and that we have little evidence from United States based studies 
that it influences racial gaps in CHD we used as an example this policy intervention to examine 
the treatment efficiency inherent in raising tobacco taxes from an equity lens. We conducted 
an empirical study to estimate the treatment effectiveness of US tobacco taxation on smoking 
and CHD mortality. Third, we simulated the equity and treatment efficiency effects of 
pharmaceutical (Statins), taxation (tobacco) and early education interventions on CHD 
mortality, and racial gaps in CHD mortality.  
 
Our scoping review of EETs in cardiovascular disease (Chapter 2) yielded a very small number 
of studies (n=6), that explicitly engaged equity and efficiency, and provided information on 
their trade-offs in the context of CVDs. Despite a paucity of evidence, we identified 2 
important lessons: (1) movement toward equity in the context of interventions on those with a 
high burden of CHD risk factors may be achieved by targeting deprived populations. Second, 
pairing these “high risk” with structural interventions can provide substantial movement toward 
not only efficiency, but also equity. Our nationally representative observational, state-level 
study of the effects of tobacco taxation on smoking prevalence and CHD mortality by race and 
gender (Chapter 3) showed that between 2005 and 2016, tobacco taxes were associated with 
reductions in both outcomes. The strongest reductions in smoking prevalence were observed 
among black non-Hispanic women, while an increase was observed among black non-Hispanic 
men. Our simulation study (Chapter 4) showed that the equity and efficiency effects of 
population health interventions in the context of reducing racial disparities in CHD may vary by 
 
 
gender. Among men, compared to no intervention, an education intervention was associated 
with the greatest reduction in racial disparities in CHD mortality, while among women, a $3 
tobacco tax intervention was associated with the greatest reduction in racial disparities in CHD 
mortality. Additionally, among men, tobacco taxes were an equity lose intervention, while for 
women, in contrast, tobacco taxes were nearly always a win-win intervention. Conversely, 
compared to tobacco taxes, statins are in some cases a win-win intervention for men, and in all 
cases a lose-lose intervention for women.  
 
Our findings support the utility of an EET lens in the reduction of racial disparities in health, 
and point to the need for more scholarship and broader integration of this lens into public 
health practice. Consideration of the interplay between equity and efficiency in population 
health interventions offers a deeper understanding of intervention effects than the 
consideration of either dimension alone. In some cases, we need not trade equity for efficiency 
in the reduction of racial inequities in health.       
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Chapter 1: Introduction 
1.1 Background 
Heart disease, including principally coronary heart disease (CHD) remains the top cause of 
mortality in the United States among adults ages 35 and older. Disparities in CHD mortality 
between socially advantaged and disadvantaged groups, such as whites and blacks1 have 
persisted for decades as shown in figure 1.1. These social gaps persist despite advances in 
treatments, preventive measures, and decreases in population prevalence of smoking that have 
done much to reduce the burden of CHD overall.1 Racial disparities in age-adjusted CHD 
mortality also vary across different demographic groups. For example, racial disparities in CHD 
mortality are greater among women than among men. Averaging over the period 1980 
through 2016, black women had a greater burden of heart disease deaths than white women, 
with an age-adjusted CHD mortality rate difference of 49 deaths per 100,000 and a mortality 
rate ratio of 1.2. From 1989 through 2016, black men had a greater burden of heart disease 
deaths than white men, with an age-adjusted CHD mortality rate difference of 38 deaths per 
100,000 and a mortality rate ratio of 1.10.2 Indeed, black non-Hispanic men and women 
experienced higher rates of CHD mortality throughout the period of 1968-2016 across most 
age groups (Appendix figures 1.1a-c), while higher rates of death among those 65 and older 
(Appendix figures 1.1d-f) are likely artifacts of survival bias. 
 
While these differences in disease burden have been well documented, there is a poor 
understanding of what interventions might narrow these differences.  An equity-efficiency 
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tradeoffs (EET) framework is a useful lens through which to consider this problem.3,4 Tradeoffs 
between equity of intervention efforts and efficiency of the returns on such efforts arise when 
public health interventions are deployed across groups of unequal socioeconomic position. 
While such interventions may achieve overall and intra-group improvement, this improvement 
may come at the expense of stable or widening inter-group differences. Therefore, in the 
context of CHD, while we have seen enormous gains in CHD-related Quality Adjusted Life 
Years (QALYs) overall, there has been a trade-off in terms of continuing (and in some cases 
widening) differences by race. While EETs have been robustly studied in the health economics 
literature,3,4 EET studies anchored in an epidemiologic or public health perspective are limited, 
and summary reviews are lacking altogether.  
 
Challenges in assessing effectiveness and EET across different types of public health 
interventions include non-exchangeable populations and limited study time horizons that 
preclude our ability to compare intervention effects across populations and over time. Agent-
Based Models (ABMs) provide an effective means to simulate a variety of counterfactual 
comparisons on a single population5 over extended time horizons. ABMs can be used to 
explore complex systems such as disease production, and these virtual world models can 




1.2 Dissertation overview 
Aiming to add to this literature, we shall take three approaches. Centrally this work seeks to 
identify public health interventions that minimize equity-efficiency tradeoffs (by achieving gains 
in both) and will reduce CHD mortality overall, while reducing disparities in CHD mortality 
between black and white populations in the United States. If we can mechanistically 
understand the conditions under which these equity-efficiency tradeoffs occur, and which 
interventions have the most favorable tradeoff profiles, we may be able to narrow racial gaps in 
CHD mortality while improving health for all. 
 
Chapter 2 provides a critical assessment of the literature in order to identify and summarize 
prior work in this area, summarizes and synthesizes EET conceptual frameworks for conducting 
empirical studies, and provides empirical examples of EET analyses applied to CHD and other 
non-communicable diseases. This approach aims to identify the questions that empirical 
studies should try to answer for a given policy, from an EET perspective. 
 
Chapter 3 presents an examination of the effects of tobacco taxation on smoking prevalence 
and CHD.  Recognizing both that tobacco taxation is an effective policy intervention on CHD,7 
and that we have little evidence from United States based studies that it influences racial gaps 
in CHD we exampled tobacco taxation as a policy intervention to examine the treatment 
efficiency inherent in raising tobacco taxes from an equity lens. We conducted an empirical 
study to estimate the treatment effectiveness of US tobacco taxation on smoking and CHD 
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mortality, to better understand racial differences in the efficiency of prevention efforts, and to 
parameterize microsimulation policy models.  
 
Chapter 4 presents simulations of the effects of pharmaceutical (Statins), taxation (tobacco) and 
early education interventions on CHD mortality, and racial gaps in CHD mortality. We 
incorporate equity as equity of outcomes across racial groups, stratified by gender, and 
efficiency as YLLs averted stratified by gender alone. Using this simulation approach, we 
examine the (1) equity effects of all interventions, and the (2) interplay of equity and efficiency 
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Figures 1.1a-c: Age-adjusted CHD Deaths per 100,000 among black, compared to white non-Hispanic 































































































































































































































































































Chapter 2: Equity Efficiency Tradeoffs in Cardiovascular Disease, 
A Scoping Review 
2.1 Abstract 
Background: Cardiovascular diseases (CVDs), including principally heart disease and stroke, 
remain top causes of morbidity and mortality in the United States and globally. While 
population gains in prevention and treatment of CVDs have improved over time, disparities 
between socially advantaged and disadvantaged groups persist. While much effort has been 
spent on maximizing efficiency, there is a need to consider equity and equity efficiency 
tradeoffs (EETs) in design and implementation of population health interventions.  
 
Methods: In order to identify and summarize prior work in this area, we conducted a scoping 
literature review of equity, efficiency and their tradeoffs in CVDs.  
 
Results: Our search yielded only 6 studies, including 2 health services program planning 
studies, and 4 simulated experimental studies. Movement toward equity in the context of high-
risk approaches to intervention may be achieved by targeting deprived populations. Pairing 
structural interventions with high risk interventions can provide substantial movement toward 
both efficiency and equity. No studies formally quantified EETs in CVD, but two used a 
heuristic called the equity-effectiveness plane to aid interpretation.  
 
Conclusions: This scoping review identified a small but emergent field of scientific investigation 
into EETs in CVD. This paucity of extant studies precludes the drawing of any clear and 
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crosscutting conclusions about which types interventions are most likely to minimize tradeoffs 
between equity and efficiency; experimental and quasi-experimental observational studies 
would help strengthen our evidence base and understanding. Much work remains in the effort 
to integrate considerations of equity and EETs into evaluations of population health 






















Cardiovascular diseases (CVDs), including principally heart disease and stroke, remain the 
leading causes of morbidity and mortality in the United States1 and globally.2 Disparities in 
CVD between socially advantaged and disadvantaged groups, such as rich and poor,3 and 
whites and blacks4 have persisted for decades. Unfortunately, large-scale public health 
interventions have often failed to close these gaps. While advances in treatments and 
preventive measures have reduced the burden of CVD marginally, these gains have been 
accompanied by a maintenance or widening of existing social gaps in disease occurrence.5   
 
An Equity-efficiency tradeoffs (EET) framework is a useful conceptual framework through which 
to consider the reduction of racial and other social disparities in CVDs because it explicitly 
acknowledges and formalizes the consideration of equity-related value judgements in decision 
making on health interventions.6,7 Centrally, tradeoffs between intervention efforts and an 
equitable distribution of the returns on such efforts may arise when intervening on groups with 
unequal social position, a situation that is near universal. Rationales for using the EET 
framework include (1) the existence of current health inequities, (2) expected future health 
inequities, or (3) the planned use of treatments that have differential effectiveness across equity 
dimensions. While this framework can provide policy makers with actionable information on 
how candidate interventions may fare in relation to equity and efficiency, there is little evidence 




The goal of this review is to provide a rigorous primer on EETs in the context of CVDs for 
epidemiologists, as an overall framework to integrate the large – but fragmented -- literature 
on health disparities in CVD, and provide a way forward to think about health disparities from a 
policy/intervention perspective, and to think about what policies and policy-features should be 
embraced depending on society’s preferences for (in)equality. This article will provide some 
broad definitions of equity, efficiency and EETs, before moving to a literature review and 
summary of findings on equity, efficiency and EETs in CVD. 
 
Equity 
Health inequities are conceptualized in a number of ways and that phrase is often used 
interchangeably with health inequalities and health disparities. The World Health Organization8 
defines health inequities as “systematic differences in the health status of different population 
groups,” noting that “these inequities have significant social and economic costs both to 
individuals and societies.” According to the Centers for Disease Control and Prevention’s 
National Center for Chronic Disease Prevention and Health Promotion,9 “Health equity is 
achieved when every person has the opportunity to ‘attain his or her full health potential’ and 
no one is ‘disadvantaged from achieving this potential because of social position or other 
socially determined circumstances.’ Health inequities are reflected in differences in length of 
life; quality of life; rates of disease, disability, and death; severity of disease; and access to 
treatment.” Yet another definition is provided by Braverman,10 who states that “Health 
disparities/inequalities are potentially avoidable differences in health (or in health risks that 
policy can influence) between groups of people who are more and less advantaged socially,” 
12 
 
Overall, whereas inequalities implies a value-free difference in outcomes, inequities implies an 
avoidable difference in outcomes that is based on social position.  
 
Equity has several formal definitions in the economics literature, including equity of health care 
utilization, distribution of health care according to need, equity of health care access, and 
equity of health outcomes.7,11 In outlining these concepts, I will refer to two hypothetical US 
adult populations – those in population A have an annual income above the poverty line, while 
those in population B have an annual income below the poverty line. Equity of health care 
utilization suggests that populations A and B access cardiovascular care at the same rates. 
Distribution of health care according to need includes two notions of equity, horizontal and 
vertical. Horizontal equity suggests that if populations A and B have the same cardiovascular 
health needs, then they should receive the same measure of health care, while vertical equity 
suggests that if population B has greater cardiovascular health care needs than population A, 
than they should receive more care. Equity of health care access suggests that both groups A 
and B should have the same access to cardiovascular health care services (i.e., quantity and 
kind). Equity of health suggests that an equitable distribution of cardiovascular care across 
populations A and B is one that would give rise to equivalent health states among those 
populations. Regarding interventions, equity of health can be thought of as equity of 
outcomes, or equal health benefits of a hypothetical intervention (e.g., statin therapy) across 





From an economics perspective, efficiency can be defined as getting the maximum output 
from a fixed input.13,14 In terms of health, efficiency can be defined in terms of treatment 
effectiveness, and maximization of quality of life, and time spent free of disability. Generally, 
these notions of efficiency are agnostic to the distributional features of a particular intervention.  
Efficiency is commonly represented in the form of Quality Adjusted Life Years (QALYs) or 
Disability Adjusted Life Years (DALYs) per dollar spent, but may simply be represented in 
QALYs or DALYs gained. QALYs allow the estimation of the number of years of life gained due 
to an intervention, adjusted for the quality of those years. In contrast, DALYs allow us to 
estimate number of years of life lost to disability, conditional on a particular intervention, in 
terms of years of life lost to early death and years lived with disability. DALYs and QALYs have 
the advantage of incorporating both morbidity and mortality, relative to treatment 
effectiveness measures that examine either morbidity or mortality. 
 
Equity Efficiency Tradeoffs  
EETs formally originated in economics, and have also been studied from the perspectives of 
cost-effectiveness and public health. The concept of EETs was formalized in economics at least 
as early as 1975,15 and was then formally linked to health in the 1990s with a pair of 
foundational economics papers.6,7 The first paper argued that the goal of health maximization – 
i.e. a focus purely on maximizing a community’s sum of QALYs, could be at odds with concerns 
about inequality in health, since such an approach would result in resources being deployed 
away from those who have lower capacity to benefit (i.e. the elderly), or who may need more 
care to achieve a QALY;6 in this way, health maximization is more about efficiency than equity, 
14 
 
whereas equity is more about the distribution rather than sum of QALYs. The second paper 
described and compared the above four definitions of equity - equality of health care 
utilization, distribution of health care according to need, equality of health care access, and 
equality of health.7 Overall, Culyer and Wagstaff suggest that equality of health should be our 
goal, because differences in health-care use and health behaviors do not justify differences in 
health across social groups.6,7 On the other hand, equality of health can lead to reductio ad 
absurdum arguments for devoting all of society’s resources to one person whose health can be 
marginally improved. An EET framework acknowledges that while the best policies are efficient 
and equitable, there is often a trade-of between equity and efficiency, and understanding the 
effectiveness of policies with respect to both is critical in order for society to meet its goals with 
respect to prioritizing health investments.  
 
The cost-effectiveness literature, which evaluates the return on a set of health outcomes per 
dollar amount invested across 2 or more interventions, has recently sought to integrate explicit 
considerations of equity into its analyses.12,16,17 One approach has been the development of 
multi-criteria frameworks and checklists that can be used for decision analysis.11,12 Similarly, 
others have proposed equity impact analyses that stratify cost inputs and health outcomes by 
equity relevant dimensions.16 Another approach is through the use of equity weights and social 
welfare functions that differentially weight QALYs according to a set of equity 
considerations,6,12,18 accounting for both equity and efficiency considerations simultaneously. 
The health equity impact plane (see figure 2.1) provides a concise heuristic framework that ties 
15 
 
together cost-effectiveness and net health equity impacts of a candidate intervention 
compared to a reference intervention.16  
 
The public health literature has focused on how and whether given interventions on a particular 
outcome affect the equity of outcomes across groups of unequal position, and typically do not 
address matters of treatment efficiency. In particular, the concept of Intervention Generated 
Inequalities19 has been advanced, and studies have shown that certain types of interventions 
tend to increase inequalities (e.g. media campaigns), while other types of interventions appear 
to decrease inequalities in health (e.g. tobacco pricing). The Equity Effectiveness Loop (see 
Figure 2.2) is a heuristic framework that aims to emulate the tools of clinical epidemiology, by 
focusing on effect modification of a given intervention effect across a given equity dimension.20 
Others have focused on methods of decomposition that estimate the effects of equalization by 
race of an intervention target (e.g. education level) on a racial disparity in a given health 
outcome, while preserving the race-specific relationships between confounders of the 
intervention target and outcome.21 While the Equity Effectiveness Loop incorporates cost-
effectiveness, studies from the public health literature generally do not explicitly address 
efficiency in terms of standard cost effectiveness analyses (e.g. DALYs averted per a fixed dollar 
amount invested) or compare outcomes across more than 1 intervention, in contrast to cost-








In order to identify and summarize prior work in this area, we conducted a scoping literature 
review22 of equity, efficiency and their tradeoffs in cardiovascular diseases. This literature review 
was aimed at answering three specific questions: (1) How are EETs empirically defined and 
studied in the context of cardiovascular diseases? (2) What types of interventions on CVDs are 
on the equity-efficiency frontier? (3) What types of interventions on CVDs provide movement 
towards efficiency, and what types provide movement towards equity?  
 
Search Strategy. We conducted a search spanning from 1975 to present of PubMed, Web of 
Science, Embase, Buisness Source Complete and EconLit using terms outlined in appendix 
table 2.1. The start of this time frame was chosen to coincide with the publication of the 
seminal economics book, Equality and Efficiency: The Big Trade-off.15 This time frame also 
starts over fifteen years prior to the publication of a key paper by Wagstaff that was the first to 
formalize the notion of equity-efficiency tradeoffs within health and health care.6 Studies that 
were identified in the search were cataloged in and de-duplicated using Zotero,23 a reference 
manager. This review included any articles, conceptual or empirical, that concern EET in CVDs.  
 
As shown in figure 2.3, we identified 1192 studies from PubMed (n=217), Embase (n=663), 
Web of Science (n=276), Business Source Complete (n=20) and EconLit (n=16). After excluding 
314 duplicates, a total of 878 unique studies were retrieved in our search, and screened for 
17 
 
eligibility, with 860 articles excluded after title review, and 12 excluded after manuscript 























Our search yielded 6 studies that we split into 2 sets – health services planning studies,24,25 and 
experimental studies.26–29  
 
Table 2.1 summarizes the contributions of health services planning studies.24,25 Banham and 
colleagues24 propose and concretize the application of an equity effectiveness framework 
called the equity-effectiveness loop (figure 2.1) to the prevention of CHD in primary care, in a 
way that is both equitable across socioeconomic status and effective, within a closed health 
care system in South Australia. Plans-Rubio25 similarly worked through technical procedures for 
allocating pharmaceutical resources within the public health service in Catalonia, Spain (1) 
according to cost-effectiveness alone and (2) according to cost-effectiveness and equity, 
projecting that the strategy based on efficiency and equity would able to save resources while 
maximizing equity.  
 
Tables 2.2 and 2.3 summarize the results of experimental studies that examine EETs in CVD.26–
29 All of the identified experimental studies were simulations. Allen and colleagues26 examined 
the efficiency (CHD-related QALY gains, Net costs), and equity (absolute inequality in CHD 
deaths between the least and most deprived quintiles) of policies to reduce trans-fatty acid 
intake among adults 25 and older in England; they found that a total ban on transfatty acids 
maximized equity and efficiency, relative to improved labelling in processed foods and a ban 




Collins and colleagues27 examined the efficiency (CVD and diabetes-related QALYs, Median 
Net Costs, Median ICER), and equity (Slope index of inequality in QALYs) of variations on CVD 
screening approaches including the current National Health Service (NHS) CVD screening and 
treatment approach, the current approach with enhanced coverage and uptake, and a version 
of the current NHS approach with enhanced targeting of the most socioeconomically deprived. 
They found the NHS checks targeted to the most deprived fifth of the population appear to be 
most likely to be effective and equitable, resulting in a win-win intervention.  
 
Kypridemos and colleagues28 simulated the future equity (Reduction in absolute and relative 
socioeconomic health inequalities) and efficiency (CVD cases prevented or postponed, net 
QALYs gained, cumulative ICER) of variations on implementation of the UK’s NHS Health 
Check – a high-risk approach that screens individuals for CVD risk and intervenes on identified 
risk factors. They compared UK’s NHS Health Check alone to 4 other scenarios (1) an optimal 
implementation (enhanced coverage and uptake) of the NHS health check, (2) NHS health 
check plus targeting to most socioeconomically deprived population quintiles, (3) NHS health 
check plus structural interventions (reduction of tobacco use and increase in fruit and vegetable 
consumption), and (4) targeted NHS health check plus structural interventions. Overall, they 
found that current NHS screening is neither efficient nor equitable; optimal screening is 
efficient but not equitable, while targeted screening is both. Adding structural policies 




Marchant and colleagues29 examined equity (Proportion of benefit – [Life Years Gained/Years of 
Potential Life Lost]), and efficiency (Number Needed to Treat to gain a life year) of initiation of 
blood pressure lowering medication using an approach called Proportional Benefit, that seeks 
to distribute relative treatment gains proportionally by gender and age, compared to the 2007 
and 2013 European Society of Cardiology/European Society of Hypertension blood pressure 
screening and treatment guidelines. They found that the proportional benefit approach traded 




















This scoping review of EETs in cardiovascular disease yielded a very small number of studies – 
only 6, that have explicitly engaged equity and efficiency, and provided information on their 
trade-offs. This paucity of extant studies precludes the drawing of any clear and crosscutting 
conclusions about which types interventions are most likely to minimize tradeoffs between 
equity and efficiency. Nonetheless, the empirical studies we identified demonstrated 2 
important lessons. First, movement toward equity in the context of high-risk interventions may 
be achieved by specially targeting deprived populations.27 Second, pairing structural 
interventions with high risk interventions can provide substantial movement toward not only 
efficiency, but also equity.28  
 
The health services program planning studies showed that health interventions on CVDs can be 
effectively designed with considerations to maximizing both equity and efficiency, utilizing 
heuristics like the equity-effectiveness loop20,24 (figure 2.2) and a 2-step process for choosing 
interventions by ranking interventions first in terms of efficiency and second in terms of equity 
(i.e. proportional-benefit).25 Additionally 2 of the studies26,27 we reviewed utilized the health 
equity impact plane16 heuristic to aid the display and interpretation of their results.  
 
This is the first study of which we are aware that brings together literature on EETs in treatment 
and prevention of CVDs. This review identifies few studies that have explicitly looked at EETs in 
CVDs, but suggests that strategies to maximize both equity and efficiency are being 
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implemented in the design of health systems and tested in the context of simulations. 
Additionally, this review suggests that all extant empirical studies of EETs in CVD are 
simulations rather than observational studies. This experimental simulation literature is 
dominated by studies using the IMPACT CVD model,26–28 which is focused on equity of 
outcome across strata of multiple social deprivation, and represents a novel examination of 
equity in the context of a well-validated UK CVD prediction model. Indeed, all of the 
experimental studies were based in Europe. Finally, while one study examined equity of 
proportional benefit by strata of age and gender,29 no studies examined equity along 
dimensions of race or ethnicity.    
 
Two commentaries that did not meet criteria for inclusion in our review, because they did not 
provide information on EETs or efficiency, are nonetheless worth mentioning and echo our 
findings. A commentary by Capewell30 and colleagues expressed the need to prioritize equity 
in evaluating the effects of large-scale UK CVD prevention efforts, noting that whereas high risk 
approaches tend to widen socioeconomic inequities in health, hybrid approaches that include 
high-risk approaches specially targeted to the most deprived groups, and population 
approaches may provide movement towards equity. Smith and colleagues31 commented on 
the unique opportunities provided by simulations in the study of health inequities in the effects 
of population health interventions, using as an example for illustration, the case of reducing 
socioeconomic inequities in CHD by intervening on tobacco use. Noting that simulations have 
many advantages to traditional studies in terms of flexibility, feasibility and the ability to 
estimate the effects of multiple types of interventions and counterfactual contrasts, they also 
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note that simulations are limited by modelling assumptions and simplifications of complex 
processes. One particular challenge they note is accurate estimation of health risk and 
intervention effects across subpopulations of greater and lesser socioeconomic deprivation.31 
Nonetheless, they point out that sensitivity analyses can be performed to test the limits of 
model assumptions.  Critically, they also note that simulations offer the opportunity to bridge 
the gap between extant data on how to reduce inequalities and the future needs to implement 
equitable CHD prevention.  
 
While EETs are generally conceptualized in the context of one intervention compared to 
another, our results demonstrate that this framework is also useful for comparing the effect of 
multiple or compound interventions, or for comparing the effect of 1 or more interventions to 
no intervention. The particular uses and usefulness of the EET framework depend on the 
resources and needs of a given policy environment. 
 
Notably absent from the results our search yielded were articles from the disparities and social 
epidemiology literatures, primarily because those articles focus on the equity dimension alone. 
Notably, the disparities literature32,33 includes work that brings a focus to racial34,35 and 
economic36 inequities. Within public health literature more broadly, the concept of Intervention 
Generated Inequalities37 has been advanced, and studies have shown that certain types of 
interventions tend to increase inequalities (e.g. media campaigns), while other types of 
interventions appear to decrease inequalities in health (e.g. tobacco pricing). In the context of 
racial and economic inequities, racism and poverty may be considered respectively 
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fundamental causes of disease – factors that index opportunities for social and material 
resources, and put more deprived populations at higher downstream risks of disease.38, 39  
 
Literature within social epidemiology places a focus on causal approaches to understanding 
health inequities. Jackson40 uses decomposition methods to estimate the effects of 
equalization by race of an intervention target (e.g. education) on a racial disparity in a given 
health outcome (e.g. CHD), while preserving the race-specific relationships between 
confounders of the intervention target and outcome. Harper gives a nice general overview of 
measurement and decomposition of health inequities.41 Others have focused on a systematic 
rubric to assessing disparities by focusing on group differences in outcome prevalence, 
exposure prevalence and effect size.42 
 
One question not addressed in the identified studies is the appropriateness of absolute vs. 
relative measures of disease occurrence. While the choice of models may depend on data 
form.43,44  it is likely best to report both relative and absolute measures. Consider for example 
that with a fixed absolute difference, that as rates go down overall, which is indeed the case 
with secular trends in cardiovascular disease, that relative differences will increase. Additionally, 
small relative differences may mask large absolute differences.  
 
Taken together, the findings of our review suggest several directions for future research. First, 
and foremost the paucity of studies yielded by our review suggests the need for a great deal of 
additional scientific work in the efforts to understand population health intervention strategies 
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that optimally maximize equity and efficiency in CVDs. Second, the field would benefit from 
explicit formulations of EETs. One great example of a relatively straight-forward heuristic is 
provided by Cookson and colleagues16 in their Health Equity Impact Plane (figure 2.1). Third as 
most of the extant studies on EETs in CVD rely on simulations, it is important that their 
assumptions are robust, and their findings validated and confirmed with observational data, 
including experimental and quasi-experimental policy studies.45 Fourth, future research could 
productively give more focus to non-healthcare-based interventions alone, a feature present in 
only one26 of our six identified studies. Fifth, the field would benefit from the examination of 
racial and ethnic inequities in health and health care. Sixth, all of the studies defined equity in 
terms of equity of outcomes, and not in terms of equity of health care utilization, distribution of 
health care according to need, equity of health care access, aspects of equity that also deserve 
to be explored in concert with equity of health outcomes. Examining these other aspects of 
equity may help us identify the main drivers of equity of outcomes. Seventh, all of the studies 
identified in our review were from either Europe or Australia, and the incorporation of studies 











This scoping review identified a small but emergent field of scientific investigation into EETs in 
CVD. All identified empirical studies were simulations, and future research could benefit the 
field by providing experimental and quasi-experimental observational data. Much work remains 
in the effort to integrate considerations of equity and EETs into evaluations of population 
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2.8 Figures and tables  
Figure 2.1 - Health Equity Impact Plane. Adapted from Cookson R, Mirelman AJ, Griffin S, et al. 















Figure 2.2 - Equity Effectiveness Loop, adapted from Tugwell et al. Applying clinical 





















Figure 2.3 - Flowchart describing the study selection process and number of articles retrieved, 





Table 2.1 – Health Services Program Planning Studies: Background, methods and findings  
Study Author and 
Publication Year 
Article Context and Purpose  Article Findings/Conclusion 
Banham (2011)24  This article is concerned with applying a framework 
that accounts for both efficiency and equity to a CHD 
prevention program based in primary care in South 
Australia. They apply an Equity Effectiveness Loop 
Framework first developed by Tugwell20 and 
colleagues as displayed in figure 2.1.   
Health services and programs can be optimized and tailored 
to improve population health in ways that are both effective 
and equitable, using health utility and health expectancy 
measures. The environment of linked and shared data within 
South Australia health systems offered an ideal opportunity 
to enact the recursive process entailed within the Equity 
Effectiveness loop framework.  
Plans-Rubio (2001)25 Set out to develop a procedure for primary 
prevention of CHD that allocates pharmaceutical 
resources based on principles of efficiency and 
equity. The context was the Public Health Service in 
Catalonia, Spain. 
They contrasted two different approaches to allocating 
resources – one focused on cost-effectiveness alone, and 
one that focused on cost-effectiveness in the first step and 
then a minimization of inequalities in health in the second 
step. They found that based on cost-effectiveness alone, 
drug therapies should be allocated in the following order:  
smoking cessation, hypertension, hypercholesterolemia; an 
approach based on cost-effectiveness and equity would 
prioritize the drug therapies in the following ordering:  
hypertension, hypercholesterolemia and smoking cessation. 
The strategy based on efficiency and equity may reduce the 
amount of resources needed by between 26%-47%, while 







Table 2.2 – Identified Experimental Studies: Study background, outcome and interventions  
Study Author and 
Publication Year 
Context and Purpose  CVD Outcome  Interventions 
Allen (2015)26 
 
Examined the health, equity and cost-
effectiveness of policies to reduce 
trans-fatty acid intake among adults 
25 and older in England.  
§ Deaths from coronary heart 
disease prevented or postponed 
1. Total ban on transfatty acids in 
processed foods 
2. Improved labelling of tranfatty 
acids in processed foods 
3. Ban on transfatty acids in   
restaurants 
4. Ban on transfatty acids in take-out 
Collins (2020)27 
 
Examined the health, equity and cost 
effectiveness of variations on CVD 
screening approaches, incorporating 
health opportunity costs.  
§ CVD and diabetes-related QALYs 1. NHS Health Checks  
2. NHS Health Checks + enhanced 
coverage and uptake   
3. Targeted NHS Health Checks, 
including particular targeting of 
the most socioeconomically 
deprived  
 
§ Examined under differing 
opportunity costs: (a) £13000 per 
QALY health production cost, and 
(b) hybrid health production cost 
(£2000 for Public Health and 




Simulated the future cost effectiveness 
and equity of the UK’s National Health 
Service (NHS) Health Check alone, 
which is a high-risk approach that 
screens individuals for CVD risk and 
§ CVD cases prevented or 
postponed 
§ Net QALYs gained 
1. Current - NHS Health Checks  
2. Targeted Current - NHS Health 
Checks, including particular 
targeting of the most 
socioeconomically deprived  
38 
 
intervenes on identified risk factors, 
compared to an optimal 
implementation of the NHS health 
check, NHS health check plus 
targeting to most deprived population 
quintile plus a set of structural 
interventions that reduced tobacco 
use through regulation  and increased 
fruit and vegetable consumption. 
3. Optimal Current - NHS Health 
Checks + enhanced coverage and 
uptake (optimal) 
4. Current + Structural interventions 





Study examined initiation of blood 
pressure lowering medication using an 
approach called Proportional Benefit, 
that seeks to distribute relative 
treatment gains proportionally by 
gender and age, compared to more 
standard high-risk strategies.  
§ Relative life-year gain (life-years 
gained-to-years of potential life 
lost ratio)  
§ Number Needed to Treat (NNT) to 
gain a life-year 
1. High-Risk strategy 1 – 2007 
European Society of Cardiology / 
European Society of Hypertension 
blood pressure screening and 
treatment guidelines – treatment 
of those with greater than or equal 
to 160/100 mm/HG have to be 
prescribed blood pressure 
lowering medication.  
2. High-Risk strategy 2 – 2013 
European Society of Cardiology / 
European Society of Hypertension 
blood pressure screening and 
treatment guidelines – same as 
2007 guidelines, but excludes 
treatment of those with high 
normal blood pressure, considers 
grade 1 hypertension and low risk 
individuals as eligible for 
treatment, and recommends 
treatment of elderly patients only 
when systolic blood pressure is > 
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160 mm/HG, although it can be 
considered in the 140-159 mm/HG 
range.  
3. Proportional Benefit approach – 
“We designed the Proportional 
Benefit strategy as an alternative 
approach to select the individuals 
eligible to BP-lowering drugs 
treatment while attaining at least 
the same overall benefit in terms 
of life-years gained as with the 
2007 European guideline 
application. This benefit was 
distributed proportionally, i.e. with 
the same ratio of number of fatal 
CVD events to prevent over the 
expected number of fatal CVD 
incident events across the different 
categories of individuals. The 
desired number of events 
prevented was used as a 
constraint to adjust the risk 
thresholds within each category of 
individuals in order to indicate BP-
lowering drugs to the mild 
hypertensives with the highest risk 





Table 2.3 – Identified Experimental Studies: Operational measure and findings 
Study Author and 
Publication Year 
Equity Efficiency Equity Efficiency Tradeoffs 
Allen (2015)26 Measure: Absolute inequality in CHD 
deaths between the least and most 
deprived quintiles.  
 
§ Total ban: reduced absolute 
inequality in CHD mortality by 
3000 deaths (15%) 
§ Improved labelling: reduced 
absolute inequality by 700 (3.4%) 
to 1500 (7%) 
§ Ban in restaurants: reduced 
absolute inequality by 700 (1.1%) 
§ Ban on take-out (fast food): 
reduced absolute inequality by 
1200 (5.9%) deaths 
Measure: Gain in QALYs  
§ Total ban: 7900 
§ Improved labelling: 2400-4000 
§ Ban in restaurants: 2100   
§ Ban on take-out (fast food): 3000 
 
Measure: Net Costs (in £ millions) 
§ Total ban: -64.1 to -246.1 
§ Improved labelling: -2.8 to -114.8  
§ Ban in restaurants: 0 to -47.4   
§ Ban on take-out (fast food): -12.5 
to -75.1 
 
Measure: No explicit formulation 
 
Findings: A total ban on transfatty 
acids maximized equity and efficiency, 
relative to other interventions they 
tested.  
 
Collins (2020)27 Measure: Slope index of inequality in 
QALYs, comparing across quintiles of 
multiple deprivation index 
 
£13000 per QALY health production 
cost 
§ NHS Health Checks: -6.463 
§ Enhanced NHS Health Checks: 
+0.431  
§ Targeted NHS Health Checks: 
+11.787  
 
Measure: Net QALYs [median net 
health benefit (QALYs per 100,000 
person years, unadjusted for 
deprivation]: 
 
£13000 per QALY health production 
cost 
§ NHS Health Checks: -0.493  
§ Enhanced NHS Health Checks: 
+0.226  
§ Targeted NHS Health Checks: 
+4.476  
Measure: No explicit measure 
 
Findings: Overall, the NHS checks 
targeted to the most deprived fifth of 
the population appear to be most 
likely to be effective and equitable, 




Hybrid Health Production Costs  
§ NHS Health Checks: +12.495  
§ Enhanced NHS Health Checks: 
+23.706  
§ Targeted NHS Health Checks: -
6.322 
 
Hybrid Health Production Costs  
§ NHS Health Checks: -19.45  
§ Enhanced NHS Health Checks: -
34.84 
§ Targeted NHS Health Checks: -
24.84 
 
Measure: Findings Median Net Costs 
§ NHS Health Checks: £3,438,881   
§ Enhanced NHS Health Checks:  
£4,397,549 
§ Targeted NHS Health Checks:  
£1,277,495 
 
Measure: Findings Median ICER 
§ NHS Health Checks: £10,608 
§ Enhanced NHS Health Checks: 
£6,654  




Measure: Reduction in absolute 
socioeconomic health inequalities 
(Equity Slope Index) 
§ Current NHS Screening: 150 by 
2030, 600 by 2040  
§ Targeted NHS Screening: 410 by 
2030, 2,900 by 2040  
§ Optimal NHS Screening: 1300 by 
2030, 7200 by 2040  
Measure: CVD Cases prevented or 
postponed 
§ Current NHS Screening: 290 by 
2030, 570 by 2040  
§ Targeted NHS Screening: 530 by 
2030, 1,200 by 2040  
§ Optimal NHS Screening: 750 by 
2030, 2,000 by 2040  
Measure: No explicit measure  
 
Findings: Current NHS screening is 
neither efficient nor equitable; optimal 
screening is efficient but not 
equitable, while targeted screening is 
both. Adding structural policies 
substantially improves equity and 




§ Current NHS Screening + 
Structural interventions: 13,000 by 
2030, 37,000 by 2040  
§ Targeted NHS + Structural 
interventions: 13,000 by 2030, 
38,000 by 2040  
 
Measure: Reduction in relative 
socioeconomic health inequalities 
(Equity Slope Index) 
§ Current NHS Screening: -24 by 
2030, -76 by 2040 
§ Targeted NHS Screening: 11 by 
2030, 120 by 2040  
§ Optimal NHS Screening: -2.1 by 
2030, -50 by 2040  
§ Current NHS Screening + 
Structural interventions: 550 by 
2030, 1200 by 2040 
§ Targeted NHS + Structural 
interventions: 550 by 2030, 1300 
by 2040  
§ Current NHS Screening + 
Structural interventions: 1,600 by 
2030, 3,300 by 2040  
§ Targeted NHS + Structural 
interventions: 1,800 by 2030, 
3,800 by 2040  
 
Measure: Net QALYs Gained  
§ Current NHS Screening: 57 by 
2030, 220 by 2040 
§ Targeted NHS Screening: 530 by 
2030, 1,200 by 2040  
§ Optimal NHS Screening: 310 by 
2030, 1700 by 2040  
§ Current NHS Screening + 
Structural interventions: 2400 by 
2030, 7,000 by 2040  
§ Targeted NHS + Structural 
interventions: 2,400 by 2030, 
7,200 by 2040  
 
Measure: Cumulative Net Cost 
(£million) 
§ Current NHS Screening: 4 by 
2030, 3.4 by 2040 
§ Targeted NHS Screening: 4.7 by 
2030, 1.3 by 2040  
§ Optimal NHS Screening: 3.9 by 




§ Current NHS Screening + 
Structural interventions: -13 by 
2030, -35 by 2040  
§ Targeted NHS + Structural 
interventions: -11 by 2030, -35 by 
2040  
 
Measure: Cumulative ICER (£/QALY) 
§ Current NHS Screening: 21,000 by 
2030, 11,000 by 2040 
§ Targeted NHS Screening: 14,000 
by 2030, 1,500 by 2040  
§ Optimal NHS Screening: 9,700 by 
2030, -2,400 by 2040  
§ Current NHS Screening + 
Structural interventions: -5,200 by 
2030, -5,100 by 2040  
§ Targeted NHS + Structural 
interventions: -4,600 by 2030, -
5,000 by 2040  
 
Marchant (2015)29 Measure: Proportion of benefit (Life 
Years Gained/Years of Potential Life 
Lost) 
 
High Risk Strategy 1 (ESH/ESC 
Guidelines 2007): 
§ Ages 35-44 – 2 
§ Ages 45-54 – 8 
§ Ages 55-64 – 13 
§ All Ages – 10 
Measure: Number Needed to Treat 
 
High Risk Strategy 1 (ESH/ESC 
Guidelines 2007): 
§ Ages 35-44 – 144 
§ Ages 45-54 – 131 
§ Ages 55-64 – 107 
§ All Ages – 114 
 
Measure: No explicit measure 
 
Findings: 
The proportional benefit approach 
traded off efficiency for equity 
compared to the high-risk strategy 1, 
but was a win-win compared to high 




High Risk Strategy 2 (ESH/ESC 
Guidelines 2013, evidence based): 
§ Ages 35-44 – 2 
§ Ages 45-54 – 8 
§ Ages 55-64 – 4 
§ All Ages – 5 
 
Proportional Benefit Approach:  
§ Ages 35-44 – 10 
§ Ages 45-54 – 10 
§ Ages 55-64 – 10 
§ All Ages – 10 
High Risk Strategy 2 (ESH/ESC 
Guidelines 2013, evidence based): 
§ Ages 35-44 – 146 
§ Ages 45-54 – 134 
§ Ages 55-64 – 144 
§ All Ages – 139 
 
Proportional Benefit Approach:  
§ Ages 35-44 – 347 
§ Ages 45-54 – 144 
§ Ages 55-64 – 84 













Chapter 3: An Examination of Race and Gender Specific Effects 
of Tobacco Taxes on Smoking Prevalence and Coronary Heart 
Disease Mortality in the United States, 2005-2016 
  
3.1 Abstract 
Background: Coronary heart disease (CHD) mortality rates in the United States (US) population 
have declined substantially since 1960, but racial and ethnic disparities persist, with higher 
rates among black non-Hispanic compared to white non-Hispanic Americans. Few studies have 
provided evidence on the heterogeneous effects of policy interventions on smoking rates and 
CHD mortality among white and black Americans. 
 
Methods: We constructed a yearly panel (2005-2016) of all 50 US States and the District of 
Columbia. For each state-year, we estimated age-adjusted smoking prevalence using the  
Behavioral Risk Factor Surveillance System, and derived CHD mortality rates per 100,000 from  
CDC’s Wide-ranging Online Data for Epidemiological Research (WONDER) system. We linked  
this panel with state-by-year data on total taxes (combined federal and state) per pack of  
cigarette from the State Tobacco Activities Tracking and Evaluation (STATE) system. We  
examined the effect of changes in tobacco taxes on (a) changes in smoking lagged by 1 year  
and (b) changes in CHD mortality lagged by 2 years, using linear regression models with state  
and year fixed effects, adjusting for per capita income and educational attainment at the state  
level. Analyses examined effects for the entire population, and estimated and assessed  
heterogeneity of effects for (1) men compared to women, (2) white non-Hispanic persons  
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compared black non-Hispanic persons, and (3) white non-Hispanic men, white non-Hispanic  
women, black non-Hispanic men and black non-Hispanic women compared to each other.  
 
Results: Tobacco taxation was associated with a percentage point reduction in age-adjusted 
smoking prevalence 1 year later of -0.4% [95% CIs: -0.6%, -0.2%] per dollar of tobacco tax 
(including federal and state), and a percent reduction in the rate of CHD mortality 2 years later 
of -2.0% [95% CIs: -3.5%, -0.5%] per dollar of tobacco tax. Taxation effects across strata of 
race-ethnicity by gender were heterogeneous for changes in smoking prevalence [f(3,50 
)=8.14; p=0.0002] but not changes in CHD mortality [f( 3,50)=1.34; p=0.2731]. For smoking 
effects, the strongest percentage point reductions were observed among black non-Hispanic 
women (-1.2% [95% CIs: -1.6%, -0.8%]), while a non-statistically significant increase was 
observed among black non-Hispanic men (1.1% [95%CIs: -0.3%, 2.5%]).  
 
Conclusion: Tobacco taxation appears to be an effective population health intervention on 
cigarette smoking prevalence and coronary heart disease mortality rates in the united states. 
Reductions in smoking prevalence were greatest among black non-Hispanic women. Future 
studies should examine the effects of tobacco taxation by age, income and education group to 
further characterize the effectiveness of this intervention, and look more closely at potential 







Heart disease remains the leading cause of death in the United States, with coronary heart 
disease (CHD) being the most common form. CHD mortality rates in the US population have 
declined substantially since 1960, paralleling advances in CHD prevention and treatment, and 
reductions in blood pressure, cholesterol levels, and smoking prevalence.1 Yet, despite the 
strong secular declines in CHD mortality, racial and ethnic disparities persist, with higher rates 
among black Non-Hispanic compared to white Non-Hispanic Americans (see figure 3.1).2,3  
 
Public health policy efforts have proven effective in reducing CHD risk factors and CHD 
mortality. Nutritional policy actions such as the New York City Trans-fat Restriction4,5 and the 
Berkeley Soda Tax6,7 reduced exposure to transfats and sugar sweetened beverages, while 
prior studies of tobacco taxes have shown that tobacco taxes are effective at reducing smoking 
and CHD.8,9 An intensive suite of policies targeting primarily diet and smoking behavior 
implemented in New York City in 2002 achieved marked declines in CVD mortality.10  Yet, 
despite the breadth of extant policy research in the area, few studies have provided evidence 
on the effects of policy interventions on racial gaps in CHD mortality.11  
 
Evidence that tobacco taxes are effective and induce larger smoking reductions among poorer 
and racial and ethnic minority populations12,13 suggests that tobacco taxes may decrease the 
CHD mortality gap between Black and White Americans. One study examining the relationship 
between tobacco taxes and hospitalizations for acute myocardial infarction and heart failure 
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using a county-level panel of inpatient hospitalizations over the years 2001 to 2008 found no 
evidence of an effect on hospitalizations for myocardial infarction, but did show evidence of 
effects on hospitalizations for heart failure across age groups.14 A prior study15 examining the 
effects of tobacco taxation on CHD mortality at the state level over the period 1970-2005 
found a statistically non-significant 5.7% (State-level clustered standard error = 4.4%) decline of 
CHD per dollar tax, five years after that tax. But this study did not capture more recent changes 
in tobacco taxes that occurred between 2005-2016, and did not examine effects by race or 
gender. 
 
Several features of the prior literature limit our ability to discern the effects of tobacco taxes on 
smoking and heart disease. First, given evidence that the physiologic benefits related to 
quitting smoking can reduce cardiovascular risk within 2 years, and that the reduction in heart 
disease risk may increase over time,16,17 there is a need to explore lags occurring 1 to 4 years 
after a given tobacco tax.  Second, prior studies have not reported on race/ethnicity effects by 
gender. Third, prior studies that have examined CHD mortality lacked analyses of the effect of 
taxation on smoking prevalence. Fourth, the study of the effect of tobacco taxes on heart 
disease mortality over 1970-2005 looked at populations 18 years old and older,15 which 
includes a large proportion of individuals who are at very low risk of heart disease (i.e., 18-34 
years old), potentially diluting the effects present in older populations that are at higher risk for 
CHD mortality. Fifth, a prior study on heart disease mortality15 defined heart disease very 
broadly (ICD 10 codes 53-68), combining coronary heart disease (i.e. ischemic heart disease), 
with Rheumatic Heart Disease, Endocarditis, and Myocarditis. Sixth, no existing study of CHD 
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mortality impact assesses tobacco tax changes after 2005. Accordingly, there are no extant and 
comprehensive studies of the race/ethnicity and gender-specific effects of recent state-level 
tobacco taxes on smoking and CHD mortality, and no national studies of taxation effects on 
CHD that extend beyond 2008.  
 
Aiming to address these research gaps, we investigate three empirical questions: 1. What are 
the effects of changes in total (state and federal) cigarette taxes on future smoking prevalence 
among black and white Americans? 2. What are the effects of changes in total cigarette taxes 
on the rate of CHD mortality among black and white Americans? 3. Are the effects of variation 
in total cigarette taxes on smoking and CHD mortality heterogeneous across strata of gender, 
















Study Population and Design 
The study population included black and white non-Hispanic non-institutionalized residents of 
all 50 U.S. states and District of Columbia from 2005-2016. The analysis was restricted to 
persons ages 35 and older, because of the low rates of CHD mortality (<5 per 100,000) in 
those under 35.  
 
We constructed a yearly state-level panel (2005-2016) of current smoking rates using the 
Behavioral Risk Factor Surveillance System (BRFSS).18 We linked this panel data with state-by-
year tobacco taxation data from the STATE System,19 and a yearly state-level panel (2005-2016) 
of CHD mortality rates from Wide-ranging ONline Data for Epidemiologic Research 
(WONDER).2   
 
Due to sparse population density, we did not include any state-years for black non-Hispanic 
men or women for the following states: Alaska, Hawaii, Idaho, Maine, Montana, New 
Hampshire, North Dakota, Oregon, South Dakota, Utah, Vermont, Wyoming. In addition, for 
black non-Hispanic men, we did not include Arizona (2005-2016), Minnesota (2007), Nebraska 





ACS – The ACS is conducted yearly, and samples approximately 3.5 million households per 
year, providing intercensal estimates of US population counts and demographic composition at 
the national and state levels.20 Additionally, the ACS provides descriptive data on age, gender, 
race/ethnicity, educational attainment, and income. These data were all available at the state 
level in single year estimates for each of the years in our 2005-2016 panel. 
 
BRFSS – The Behavioral Risk Factor Surveillance System (BRFSS) is a state-based national panel 
survey that is conducted annually by telephone.18,21 The BRFSS consists of a standard core of 
questions that are not modified from state to state, including health risk behaviors like cigarette 
smoking and alcohol use, chronic medical conditions, and use of preventative services. In 2011, 
the BRFSS underwent a change in sampling methodology that shifted their sampling frame to 
include not only landlines, but also cellular phones.22 
 
PUMS – The Public Use Microdata Sample (PUMS)23 is an individual level subsample of 
participants captured in the ACS, for each US state and the District of Columbia. It allows for 
more flexibility in estimates of US population demographics compared to the ACS. These data 
were all available at the state level in single year estimates for each of the years in our 2005-
2016 panel. 
 
STATE - The State Tobacco Activities Tracking and Evaluation (STATE) System19 is maintained 
by the CDC and provides data on annual measures of federal and state-level tobacco taxes. 
Included in the data are (1) state tax per pack (in dollars), and (2) federal tax per pack (in 
52 
 
dollars). These data were extracted from The Tax Burden of Tobacco, an annual publication 
produced by an economic consulting firm, with single year estimate data available for each of 
the years in the 2005–2016 period.  
 
WONDER - The Wide-ranging ONline Data for Epidemiologic Research (WONDER)2 dataset is 
maintained by the CDC and provides national and state-level mortality rates, including CHD, 
by race, ethnicity and gender. These data are based on death certificates for all 50 states and 




Tobacco Taxes: We used total state and federal taxes as our exposure, measured in dollars per 
pack of cigarettes. Nominal annual taxes were adjusted for inflation to reflect 2016 dollars, but 
were not adjusted for regional differences in purchasing power.  
 
Outcome  
Smoking Prevalence: Smoking prevalence was estimated using BRFSS data, as the proportion 
of respondents ages 35 and older who were current smokers in a given state in a given year. 
Current smoking was defined as a binary variable taking the value of one if a respondent 
reported having smoked at least 100 cigarettes in their lifetime and reported currently smoking 
cigarettes some days or every day, and zero otherwise. Current smoking status was imputed for 
BRFSS observations with missing data (1.7% overall), using the SAS MI procedure. Smoking 
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status was imputed using demographic and alcohol use variables. Estimates of state-by-year 
current smoking prevalence were weighted with BRFSS individual weights, which adjust for 
sampling design and survey non-response. Smoking prevalence was estimated separately by 
gender and race/ethnicity (white non-Hispanic men, white non-Hispanic women, black non-
Hispanic men, black non-Hispanic women), and combined across 10 imputation data sets. 
Notably, the 2011 BRFSS sampling redesign led to an increase in estimated of smoking 
prevalence.22  
 
CHD Death Rate: Age-adjusted CHD death rates per 100,000 population among adults ages 
35 years and older were obtained from WONDER, with CHD deaths identified using ICD-10 
codes I20-I25 for the period of 2005-2016, and death rates calculated as deaths per 100,000 
population. Age-adjustment of CHD death rates in WONDER estimates was performed using 
the direct method of age-standardization using the 2000 US Census. CHD death rates were 
estimated separately for each state and each year, and further stratified by gender and 
race/ethnicity. All estimates of effects on CHD were weighted with state-year denominators 
from the ACS to allow for national estimates. 
 
Covariates used in adjusted CHD and smoking estimates 
State- and year- indicators: we included indicators for each state to adjust our analyses for all 
fixed characteristics of states. We included indicators for each year (2005–2016) to account for 
all national trends, including the 2011 BRFSS sampling frame redesign, that could bias the 




Area-level Education: Percent with some college or more education (ages 35 and older) for 
each state-year was computed using annual, single-year PUMS state estimates and raking them 
to ACS marginal estimates of (a) education by race/ethnicity and (b) gender separately, to 
obtain estimates by strata of race/ethnicity by gender.  
 
Area-level Income: Median per-capita income (ages 35 and older) for each state-year was 
computed using PUMS data, by strata of race/ethnicity by gender. 
 
Weighting 
Our regression models of smoking prevalence and CHD mortality were weighted by state-year 
population to allow for national estimates. Estimates of taxation effects on smoking prevalence 
were weighted with the sum of BRFSS study weights by state-year, while our primary analyses 
of taxation effects on CHD were weighted with state-by-year population denominators from 
the ACS. All state-year weights were specific to race/ethnicity and gender, so that white non-
Hispanic men, white non-Hispanic women, black non-Hispanic men and black non-Hispanic 
women each have their own set of state-year weights.  
  
Analytic Approach 
We conducted an observational, state-level, panel study to examine the effect of tobacco taxes 
on rates of smoking and CHD mortality among black and white populations in the United 
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States. We allowed 1 year for the effects of taxation on smoking prevalence to accrue, and 1 
additional year for the effects of taxation on CHD mortality to accrue.  
 
We estimated 4 multiple linear regression models [see box 3.1] including state and year fixed 
effects to assess whether within-state variation in tobacco taxes, lagged by 1 year, was 
associated with smoking rates. We then computed marginal effects for the percentage point 
change in smoking prevalence per dollar tobacco tax (1) for the overall study population using 
model 1.1, (2) by gender strata using model 1.2, (3) by strata of race/ethnicity using model 1.3, 
and (4) by strata of race/ethnicity by gender using model 1.4. Finally, we compared marginal 
effects within model, using f-tests to assess homogeneity of estimates. All standard errors were 
clustered at the state level.  
 
We then estimated 4 multiple linear regression models [see box 3.2] including state and year 
fixed effects to assess whether variation in tobacco taxes, lagged by 2 years affected CHD 
rates. For interpretation purposes, we modeled the log of CHD rates, which allowed us to 
estimate percent changes in CHD per dollar increase in tobacco tax. We then computed 
marginal effects for percent changes in smoking prevalence per dollar tobacco tax (1) for the 
overall study population using model 2.1, (2) by gender strata using model 2.2, (3) by strata of 
race/ethnicity using model 2.3, and (4) by strata of race/ethnicity by gender using model 2.4. 
Finally, we compared marginal effects within model, using f-tests to assess homogeneity of 





All models constructed for sensitivity analyses of smoking prevalence followed the form of 
models 1.1-1.4 [see box 3.1], while all models constructed for sensitivity analyses of CHD rates 
followed the form of models 2.1-2.4 [see box 3.2]. 
 
Model Form. In order to examine the sensitivity of our results to model form, we constructed 
models of the effects of taxes on smoking prevalence and CHD mortality using generalized 
linear models with logistic and Poisson links, respectively.  
 
Negative Control. We repeated our analysis of mortality lagged by 2 years, but with measures 
of pooled accidental injury mortality rates [including transport accidents (ICD-10 Codes: V01-
V99) and other external causes of accidental injury (ICD-10 Codes: W00-X59)], rather than CHD 
mortality rates, as a negative control or falsification test.  
 
Local Autonomy. One concern in the evaluation and study of the effects of state-level taxes is 
sub-state variation in policy and its implementation. In order to examine the degree to which 
our estimates of taxation effects on smoking prevalence and CHD may have been affected by 
local autonomy, we conducted a sensitivity analysis. We adjusted for the Index of Local 
Government Autonomy (ILGA),24 which provides a state-specific index score ranging from 1 
(most autonomy) to -1 (least autonomy). The ILGA is comprised of three empirically estimated 
factors – local government importance, local government discretion, and local government 




Age adjusted CHD deaths per 100,000 decline throughout the period (figure 3.1a), with the 
highest rates of deaths among black non-Hispanic men, followed by white-non-Hispanic men, 
black non-Hispanic women, and white non-Hispanic women. As shown in figure 3.2, real 
tobacco taxes rose through the study period, with a clear upward inflection between 2008 and 
2009. Averaging combined federal and state tobacco taxes over the years 2005-2008, we 
observed a mean of $1.67 (SD=$0.76; range: $0.51-$3.53), while averaging over the years 
2009-2016, we observed a mean of $2.48 (SD=$1.02; range: $1.18-$5.90). As shown in 
appendix figure 3.1, the 3 states with the lowest total tobacco tax rates at the end of the 
period were Missouri, Virginia and Georgia, while those with the highest tax rates were New 
York, Connecticut and Rhode Island.  
 
Appendix table 3.2 shows that weighted population frequencies from the BRFSS are 
comparable to ACS estimates throughout the study period by gender, race/ethnicity and 
gender by race-ethnicity.  Figure 3.3 shows that the weighted national BRFSS smoking 
prevalence generally declines for all demographic groups, punctuated by a change in sampling 
methodology between 2010 and 2011 that resulted in a rise in estimated smoking 
prevalence,22 and thus an offset between the earlier and later periods. Black non-Hispanic men 
had the highest prevalence of smoking throughout the study period, followed by white non-
Hispanic men, black non-Hispanic women, and white non-Hispanic women. Proportion with 
some college or more was highest among white non-Hispanic men and women, followed by 
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black non-Hispanic women and black non-Hispanic men, as shown in appendix figure 3.2. 
Median income at the state level, in 2016 dollars, was highest among white non-Hispanic men 
followed by black non-Hispanic men, white non-Hispanic women and black non-Hispanic 
women, as shown in appendix figure 3.3.  
 
Tobacco Taxation Effects on Percentage Point Change in Smoking Prevalence. Appendix figure 
3.3 shows the effect of total tobacco taxes, per dollar tax on smoking prevalence 
contemporaneously and lagged by 1-5 years, with clear effects in lags 0-4. Table 3.1 shows the 
effects of tobacco taxation, per dollar, on percentage point change in smoking prevalence 
lagged by 1 year. The estimated percentage point reduction in smoking prevalence per dollar 
tobacco tax was -0.4% [95% CIs: -0.6%, -0.2%]. Among men, the estimated effect was -0.1% 
[95% CIs: -0.5%, 0.3%], while among women the estimated effect was -0.5% [95% CIs: -0.8%, -
0.2%]; an f-test suggested non-homogeneity (f(1,50 )= 4.31; p=0.0431) of these estimates. 
Among white non-Hispanic persons, the estimated effect was -0.5% [95% CIs: -0.8%, -0.2%], 
while among black non-Hispanic persons, the estimated effect was -0.2% [95% CIs: -0.9, 0.4]; 
an f-test suggested homogeneity [f(1,50 )= 0.44; p= 0.5091] of these estimates. Finally, we 
examined effects by both gender and race-ethnicity, and estimated effects among white non-
Hispanic men of -0.4% [95% CIs: = -0.8%, 0.0%], among black non-Hispanic men of 1.1% 
[95%CIs: -0.3%, 2.5%], among white non-Hispanic women of -0.6% [95%CIs: -0.9%, -0.4%], and 
among black non-Hispanic women of -1.2% [95% CIs: -1.6%, -0.8%]; an f-test suggested non-




Taxation Effects on Percent Changes in CHD Mortality Rate. Appendix figure 3.5 shows the 
effect of total tobacco taxes, per dollar tax on percent changes in CHD contemporaneously 
and lagged by 1-5 years, with clear effects in lags 2-4. Table 3.2 shows the effects of tobacco 
taxation, per dollar, on age-adjusted CHD mortality rates among white non-Hispanic men and 
women and black non-Hispanic men and women, lagged by 2 years. The estimated effect per 
dollar cigarette tax on percent changes in CHD mortality rates for the overall study population 
was -2.0% [95% CIs: -3.7%, -0.5%]. Among men, the estimated effect was -2.1% [95%CIs: -
3.5%, -0.6%], while among women the estimated effect was -1.9% [95%CIs: -3.7, 0.1]; an f-test 
comparing these estimates suggested homogeneity [f (1,50)=0.18, p=0.6738]. Among White 
non-Hispanic persons, we found the estimated effect per dollar tax on percent changes in CHD 
mortality rates to be -1.8% [95% CIs: -3.7%, 0.1%], while among black non-Hispanic persons, 
the estimated effect was -3.4% [95% CIs: -4.5%, -2.2%]; these estimates appear to be 
homogenous [f (1,50 )=2.13; p=0.1511]. Finally, we examined estimates of taxation effects by 
race and gender, and estimated effects among white non-Hispanic men of -1.8% [95%CIs: -
3.4%, -0.3%], among black non-Hispanic men of -3.0% [95% CIs: -4.6%, -1.3%], among white 
non-Hispanic women of -1.5% [95% CIs: -3.5%, 0.5%], and among black non-Hispanic women 
of -3.4% [95% CIs: -4.8%, -2.1%]; an f-test [f( 3,50)=1.34; p=0.2731] suggested homogeneity of 
these estimates.  
 
SENSITIVITY ANALYSES 
Model Form. As shown in appendix table 3.2, when taxation effects on smoking prevalence are 
estimated using generalized linear models with a logit link, the patterns of effect and 
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comparisons of estimates for homogeneity are approximately the same as in the linear models 
(table 1). As shown in appendix table 3.3, when we use generalized linear models with a 
Poisson link to model CHD mortality (rather than the natural log of CHD mortality), the 
presence and ordering of effects roughly match those estimated in the linear models (table 
3.2), as do the results of tests for homogeneity. Notably, these models estimate a marginal 
absolute effect of -5 deaths [95% CIs: -9, -2] per 100,000 for the overall population of black 
and white non-Hispanic.   
 
Local Autonomy. In order to account for local autonomy within state, we re-ran the linear 
models presented in tables 3.2 and 3.3, but added to our models the state-level ILGA variable. 
As shown in appendix tables 3.4 and 3.5, the ILGA-adjusted results were nearly identical.  
 
Falsification. As a falsification exercise, we examined the effect of tobacco taxes on pooled 
accidental injury mortality rates, including transport accidents (ICD-10 Codes: V01-V99) and 
other external causes of accidental injury (ICD-10 Codes: W00-X59) to see whether the pattern 
of coefficients was similar to those observed for CHD mortality. As shown in appendix table 
3.6, there was no discernible pattern of effects that is similar to those seen for CHD mortality 










3.5 Discussion  
This nationally representative observational, state-level, panel study showed that between 
2005 and 2016, tobacco taxation was associated with a percentage point reduction in age-
adjusted smoking prevalence 1 year later of -0.4% [95% CIs: -0.6%, -0.2%] per dollar of 
tobacco tax, and an average percent reduction in the rate of CHD mortality 2 years later of -
2.0% [95% CIs: -3.7%, -0.5%] per dollar of tobacco tax. In absolute terms, tobacco taxes were 
associated with an average reduction in CHD deaths of -5 [95% CIs: -9, -2] per 100,000.  
Taxation effects across strata of race-ethnicity by gender were heterogeneous for changes in 
smoking prevalence [f(3,50 )=8.14; p=0.0002] and homogeneous for changes in CHD mortality 
[f( 3,50)=1.34; p=0.2731]. For smoking effects, the strongest percentage point reductions were 
observed among black non-Hispanic women (-1.2% [95% CIs: -1.6%, -0.8%]), while an increase 
was observed among black non-Hispanic men [1.1% [95%CIs: -0.3%, 2.5%]].  
 
The effects of taxation on reducing CHD mortality observed in this study are consistent with 
those seen in the study by Bowser and colleagues,15 albeit smaller and more precise. In 
addition, the CHD mortality effects observed in this study are consistent with those seen in a 
prior study by Ho14 of the relationship between tobacco taxes and heart failure 
hospitalizations;14 given that atherosclerosis is a cause of heart failure. This study expands upon 
the work of Bowser15 and colleagues by examining the effects of tobacco taxation on CHD 
between 2005-2016, and by examining exposure lags that lie between 0 and 5 years. In 
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addition, this expands upon prior work by Bowser15 and Ho14 by examining race/ethnicity-by-
gender specific estimates of the effects of taxes on CHD outcomes.  
 
The findings of this study suggest that tobacco taxation is an effective intervention on reducing 
smoking prevalence and CHD mortality among white and black non-Hispanic populations in 
the United States. While taxation effects on smoking prevalence appear to be most strongly 
associated with reductions among black non-Hispanic women, they appear to be harmful 
among black non-Hispanic men. In contrast, taxation effects on CHD appear homogeneous. 
Effects of tobacco taxes on smoking and CHD may be stronger among black non-Hispanic 
women for several reasons. First, price elasticity of tobacco may be greatest for black non-
Hispanic women because they have the lowest per-capita income compared to other 
race/ethnicity-gender groups. One question arises however, as to why tobacco taxation was 
associated decreases in CHD mortality 2 years after a given tax for black non-Hispanic men, 
despite increases in smoking prevalence 1 year after a given tax. One reason for this 
inconsistency could be the reduction in smoking frequency, which is not included in this study, 
despite an increase in smoking prevalence, which may occur due to targeted marketing 
designed to offset tax increases.25 A second explanation for this pattern could be the 
emergence or strengthening of a cigarette black market, including the sale of single cigarettes 
or “loosies,” that is most accessible to and targeted toward black non-Hispanic men.22,26 Third, 
it is possible that increases in smoking prevalence among black non-Hispanic men are 
concentrated in specific age groups – perhaps younger groups that are at lower risk of CHD 
mortality, and cannot be observed without age-stratified estimates. Fourth, the decreases in 
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CHD mortality, following increases in smoking prevalence, per dollar tax, could be driven by 
changes in competing risks for conditions like stroke.27 Finally, even if smoking prevalence 
increases among black non-Hispanic men that exposure may be offset to some degree by a 
reduction in secondhand smoke.   
 
The findings of this study should be considered in the context of several limitations. First, the 
BRFSS sampling methodology, which underlies our estimate of smoking prevalence underwent 
a substantial change in the middle of the study period, in 2011, resulting in our reporting of 
period-stratified estimates. Despite this, we control in our analysis for year, which adjusts for 
any level differences in smoking prevalence in the post-period. Second, the BRFSS is 
conducted at the state level, so it is possible that state-level differences in sampling and 
module order may have resulted in measurement variance for smoking prevalence across 
states. A third limitation to this study is the lack of more detailed data on quit and initiation 
rates and smoking frequency. These data would allow us to clarify the effects of taxation on 
smoking behavior, critically providing the opportunity to further understand the dynamics of 
taxation on smoking among black non-Hispanic men. Fourth, it is worth noting the high R2 
values for the smoking and CHD models. However, this appears to be due in part, to the 
inclusion of state and year fixed effects, and the R2 values we observed were similar to those 
observed in a similar study of taxation and CHD by Bowser and colleagues.15 Fifth, the 
relatively wide confidence intervals around effects on smoking prevalence and CHD reveal 
uncertainty in our estimates. Nonetheless, the marginal point estimates and estimates by strata 
of race/ethnicity-by-gender are clear and convincing.  
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Future studies could fruitfully examine the effect of taxation on tobacco consumption with data 
that gets at frequency of tobacco use (i.e. number of cigarettes per day), in addition to 
smoking initiation and quitting. These data may more precisely capture the effects of taxation 
on smoking and better explain links between taxation effects on smoking and those on heart 
disease. In addition, future studies could productively examine the effects of tobacco taxes on 
smoking behavior and CHD by age, income and education group, in order to further 
understand the dynamics of this ongoing population health intervention. If the effects of 
tobacco taxation on smoking were heterogeneous by age, that could help explain why taxation 
increases smoking prevalence among black men while decreasing CHD. Finally, it is possible 
that the reduction in CHD among black men is caused by competing risks of death due to 
















Tobacco taxation appears to be an effective population health intervention on cigarette 
smoking prevalence and coronary heart disease mortality among white and black non-Hispanic 
men and women. Reductions in smoking prevalence were greatest among black non-Hispanic 
women, while increases in smoking prevalence were observed among black non-Hispanic men. 
Future studies should examine the effects of tobacco taxation by age, income and education 
group to further characterize the effectiveness of this intervention, and more closely look at 
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3.8 Boxes, figures and tables 











Figures 3.1a-c: Age-adjusted CHD Deaths per 100,000 among black, compared to white non-Hispanic men and women ages 35+: 
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Figure 3.2 – Average total tobacco taxes per pack by year: Box and whiskers plots with median and interquartile range for total 











Figure 3.3 – Age-adjusted national prevalence of current smoking for white non-Hispanic men and women, and black non-Hispanic 




(*In 2011, the BRFSS changed their sampling frame to include not just random-digit dial of household phones, but also cellular 
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1,966 -0.4% -0.6% -0.2 
Model 1.1:  
R2= 0.7408; Root MSE= 
0.02026 
-- - 
Men 976 -0.1% -0.5% 0.3% Model 1.2:  
R2= 0.7696; Root MSE= .01942 f(1, 50)= 4.31  p=0.0431  Women 990 -0.5% -0.8% -0.3% 
White non-Hispanic  1,122 -0.5% -0.8% -0.2% Model 1.3:  
R2=0.8188; Root MSE= 0.01717 f(1,50 )= 0.44  p=0.5091   Black non-Hispanic 844 -0.2% -0.9% 0.4% 
White non-Hispanic men 561 -0.4% -0.8% 0.0% 
Model 1.4:  
R2= 0.8574; Root MSE=0.0157 f(3,50 )=8.14 p=0.0002  
Black non-Hispanic men  415 1.1% -0.3% 2.5% 
White non-Hispanic women 561 -0.6% -0.9% -0.4% 
Black non-Hispanic women 429 -1.2% -1.6% -0.8% 
 
§ - multiplied by 100 for interpretation;  








Table 3.2 – Effect per $1 of tobacco tax on the natural log of age-adjusted Coronary Heart Disease Mortality among Americans 35 



















-2.0% -3.7% -0.5% 
Model 2.1:  
R2= 0.9672, Root MSE=0.06959 - - 
Men 861 -2.1% -3.5% -0.6% Model 2.2:  
R2= 0.9787, Root MSE=0.05715 f(1,50 )=0.18 p=0.6738  Women 869 -1.9% -3.7% -0.1% 
White non-Hispanic  1020 -1.8% -3.7% 0.1% Model 2.3:  
R2= 0.9773, Root MSE= 0.05877 
f(1,50 )= 
2.13 p=0.1511 Black non-Hispanic 710 -3.4% -4.5% -2.2% 
White non-Hispanic men 510 -1.8% -3.4% -0.3% 
Model 2.4:  
R2= 0.9903, Root MSE= 0.03979 
f( 3,50)= 
1.34 p=0.2731 
Black non-Hispanic men  351 -3.0% -4.6% -1.3% 
White non-Hispanic women 510 -1.5% -3.5% 0.5% 
Black non-Hispanic women 359 -3.4% -4.8% -2.1% 
 
§ - multiplied by 100 for interpretation  








Chapter 4: A Microsimulation of Equity-Efficiency Tradeoffs in 
Population Health Interventions for Coronary Heart Disease 
Mortality Among Black and White Americans 
 
4.1 Abstract 
Background: Heart disease, principally coronary heart disease (CHD) is the leading cause of 
mortality among US adults ages 35 and older. Disparities in CHD mortality between socially 
advantaged and disadvantaged groups, such as whites and blacks have persisted for decades. 
While these differences in disease burden have been well documented, there is a poor 
understanding of how to optimally narrow these differences while maintaining overall 
improvement in CHD mortality. An equity-efficiency tradeoffs (EET) framework may be a useful 
lens through which to consider this problem. 
 
Methods: We performed agent-based micro simulations to study the effects of taxation ($2 and 
$3 tobacco tax), pharmaceutical (Statins), and early education interventions on CHD mortality, 
and racial gaps in CHD mortality, incorporating efficiency as Years of Life Lost (YLL) averted. 
We initialized 4 cohorts of simulated agents including white non-Hispanic men and women, 
and black non-Hispanic men and women, ages 45-64, using demographic data from the 
American Community Survey and Public Use Microdata Sample, and CHD risk factor data from 





Results: This simulation study shows that among men, compared to no intervention, the 
education intervention was associated with the greatest reduction in annualized racial 
disparities in CHD mortality (Ratio of ratio (RoR)=0.96; DID=-7.6 per 100,000), while among 
women, the $3 tobacco tax intervention was associated with the greatest reduction in 
annualized racial disparities in CHD mortality (RoR=0.96; DID=-4.3 per 100,000). Among men, 
tobacco taxes increased annualized racial disparities in CHD mortality (RoR=1.11; +17.3 CHD 
deaths per 100,000). For men overall, each tax and statins intervention resulted in YLLs 
averted, compared to no intervention, with the greatest gains seen for the strong statins 
intervention (777 per 100,000). For women overall, each intervention was associated with 
increases in YLLs averted, with the greatest gains seen for the $3 tobacco tax (287 per 
100,000). Examining equity and effectiveness dimensions together, and comparing statins and 
taxation interventions, we found that for men, tobacco taxes were an equity lose intervention 
compared to statins, while for women tobacco taxes were nearly always a win-win intervention.  
 
Conclusions: The equity-efficiency trade-off profile of population health interventions in the 
context of reducing racial disparities in CHD may vary by gender. Among women, tobacco 









Racial disparities in Coronary Heart Disease (CHD) mortality rates have persisted for decades 
and remain an important intervention target for policymakers.1 While these differences in 
disease burden have been well documented, there is a poor understanding of what 
interventions might narrow these differences. Literature on intervention generated inequalities 
suggests that interventions on tobacco price such as taxation may be among the most 
promising types of interventions in terms of reducing inequalities by income and education,2 
while there is evidence that ethnic minorities experience greater health gains compared 
majority groups.3,4 
 
An equity-efficiency tradeoffs (EET) framework may be a useful lens through which to consider 
this problem.5,6 Tradeoffs between equity of intervention efforts and efficiency of the returns on 
such efforts arise when public health interventions are deployed across groups of unequal 
socioeconomic position. While such interventions may achieve overall and intra-group 
improvement, this improvement may come at the expense of stable or widening inter-group 
differences. Therefore, in the context of CHD we achieved enormous gains in mortality overall7 
at the expense of trade-offs in terms of continuing inequities by race.1 To date, to the best of 
our knowledge, tradeoffs between equity and efficiency across interventions for heart disease 




A central challenge facing the use of EET frameworks to inform the reduction of existing 
inequities is limited evidence on the comparative cost-effectiveness of particular interventions 
on the same population. Human experiments are costly, are typically not powered to detect 
effect heterogeneity across different groups, and have limited time horizons. Integrating quasi-
experimental policy evaluation with simulation models offers an approach to establish 
treatment impact in different groups and to simulate how these impacts propagate over time.8 
Simulation studies provide an opportunity to study the effects of a single simulated population 
over time, and a body of work has employed simulation methods to examine the effects of 
various policy interventions on heart disease.9 Few simulation studies have examined the 
effects of policy interventions on racial inequities in CHD, but a recent simulation10 of high-risk 
and population-wide interventions on CHD risk factors demonstrated the potential to examine, 
in-silico, the differential effects of population-level interventions. Agent-Based Models (ABMs) 
are a class of flexible simulation models that facilitate a variety of counterfactual comparisons 
on a single population11 over extended time horizons. ABMs can be used to explore complex 
systems such as disease production, and these virtual world models can inform our ability to 
understand the observable world.12 Specifically, simulations provide an optimal technology for 
the testing and fine-tuning of population health interventions aimed at reducing social 
inequalities and increasing health equity.8  
 
We performed agent-based microsimulations of the effects of pharmaceutical (Statins), taxation 
(tobacco) and an education intervention on CHD mortality, and racial gaps in CHD mortality, 
incorporating equity as annualized rate ratios and rate differences of CHD mortality, and 
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incorporating efficiency as return on Years of Life Lost (YLLs) averted. We aimed to answer the 
following questions: 1. What are the equity and efficiency profiles of tobacco taxes, statins, and 
early childhood interventions on educational attainment for their effects on CHD in black and 
white populations? 2. Which of these interventions provide movement towards efficiency, and 
what types provide movement towards equity? 3. What are the EET profiles for statins and an 
early childhood education intervention, relative to tobacco taxes in reducing racial disparities in 





















We performed agent-based micro simulations to examine the effects of a statins intervention 
on those who are at high risk for CHD, a population-wide tobacco taxation intervention, and an 
early education intervention on CHD mortality, racial gaps in CHD mortality, and Years of Life 
Lost (YLLs) from CHD averted. Model input parameters are shown in table 4.1.  
 
Model Initialization 
Our population of 67,649,943 simulated agents was initialized to serve as a to-scale 
approximation of white non-Hispanic men (N=28,579,389), black non-Hispanic men 
(N=4,473,314), white non-Hispanic women (N=29,414,299) and black non-Hispanic women 
(N=5,182,941), ages 45-64, living in all 50 United States and the District of Columbia. We 
initialized our synthetic population with demographic characteristics of gender, race/ethnicity, 
age and educational attainment from the American Community Survey 201513 estimates and 
corresponding Public Use Microdata Sample (PUMS)14 files. Using this data, a synthetic 
population of individual people within households was created, as described in Appendix 4.  
 
Coronary Heart Disease Risk Factors 
We used the National Health and Nutrition Examination Survey (NHANES),15 which is a 
nationally representative probability survey, over the period of 2008-2016, to assign agents 
CHD risk factor values. We excluded persons with diabetes because we used the Framingham 
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Heart Study (FHS) Hard Coronary Heart Disease 10-year risk algorithm,18 which requires the 
exclusion of persons with diabetes, as a component of our statins intervention as further 
described below. We divided the NHANES population into 32 strata of risk profiles, defined by 
the presence of 5 binary risk factors – hypertension medication, cigarette smoking status, 
systolic blood pressure (> 130 mm/HG), HDL (<50 mg/dl), and total cholesterol (>160 mg/dl), 
in order to account for clustering of risk factors. We then mapped these 32 strata to our 
synthetic population of white and black non-Hispanic Americans, and assigned risk factor value 
sets to those population strata within our simulations. Within risk profile strata, we randomly 
sampled individuals from NHANES data, in order to assign risk factor value sets, including 
smoking status, systolic blood pressure, hypertension medication status, HDL cholesterol, LDL 
cholesterol and total cholesterol. 
 
Coronary Heart Disease Mortality 
CHD Mortality. Coronary heart disease mortality will be assessed with the SCORE algorithm, 
which predicts CHD mortality at 10 years of follow up, and is the only algorithm we are aware 
of that predicts mortality related to CHD in particular.  The SCORE project16 developed a set of 
scoring equations for 10-year risk of fatal CHD, pooling 12 European cohort studies consisting 
of 205,178 persons who experienced 5652 CHD deaths. Their risk scoring equations use as 
inputs, a set of risk factors that include gender, total cholesterol, ldl cholesterol, systolic blood 
pressure, smoking status, and hypertension medication treatment status.  
 
Intervention Components and Strength  
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Statins. The statins intervention was implemented by increasing the proportion of statin use 
among those who met criteria similar to that of the United States Preventive Services Task 
Force recommendation of statin use for primary prevention of cardiovascular disease17 among 
those with (a) 1 or more of the following risk factors: dyslipidemia (defined as LDL-C > 130 
mg/dl or HDL < 40 mg/dl), hypertension (defined as systolic blood pressure of >130 mm/HG), 
or smoking, and (b) greater than or equal to a 10% 10-year risk of CVD. As our simulated 
cohort did not include anyone who has diabetes, we did not assess for this factor in our 
intervention. As we did not compute 10-year risk of CVD in this model, we instead used 10-
year risk of hard CHD, which is defined as either myocardial infarction or death, and is assessed 
with the Framingham Heart Study (FHS) Hard Coronary Heart Disease 10-year risk algorithm.18 
Uptake of statins was informed by estimates of statin use from our baseline population by 
race/ethnicity and gender strata. We used these estimates of statin use in our baseline 
population as a proxy for expected statin uptake in our intervention, and included two 
intervention scenarios among those meeting criteria similar to USPTF recommendations: 
moderate uptake statins - a 300% increase, and strong uptake statins - a 500% increase in the 
use of statins over 2 years. Those who took up statins in the intervention period experienced 
changes in LDL (28.2% decrease) and HDL cholesterol (2.9% increase). These treatment effects 
were estimated using data from a meta-analysis19 of randomized controlled trials examining the 
benefits of low-moderate dose statins among those with cardiovascular risk but no history of 
cardiovascular disease; no effect heterogeneity was observed for those with compared to 
without diabetes. Intervention costs were estimated at $78.17/year as reflected in table 4.1, 
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including $48/year for moderate intensity statins, $19/year for a lipid panel, $1.17/year for a 
liver panel, and $10/year for a Physician Visit.  
 
Tobacco Taxes. The effect of tobacco taxes on smoking prevalence was estimated for black 
and white non-Hispanic populations by gender and was estimated using a panel constructed 
with smoking prevalence estimates from the BRFSS20 and taxation estimates from the STATE 
system,21 adjusted for state and year fixed effects, and state level income and educational 
attainment. We included two intervention scenarios – a $2 and $3 increase in combined federal 
and state tobacco taxes over 2 years. Agents who quit smoking as a result of the intervention 
were reassigned total cholesterol, HDL cholesterol, and systolic blood pressure sampled from 
strata of non-smokers. We assumed that this intervention would not be associated with any 
additional tobacco regulatory costs, and would thus not be associated with any cost for 
implementation.  
 
Education. The intervention on Education was an attempt to simulate a best-case scenario 
whereby we were able to shift the distributions of some education or more among black non-
Hispanic men and women to reflect those of white non-Hispanic men and women, by state. In 
order to achieve this, we took a random sample of black non-Hispanic men and women from 
low education status, and reassigned their CHD risk factors to reflect those sampled from 
individuals in the high education group. As this intervention was more of a hypothetical, toy 




Years of Life Lost  
 
We estimated Years of Life Lost to CHD by randomizing CHD deaths observed by the end of 
the SCORE algorithm 10-year fatal CHD prediction period back to specific years within the 10-
year period, and then subtracting their age at death from their life expectancy, stratified by 
education status (table 4.1). 
 
Model Calibration 
We calibrated our baseline (i.e., no intervention) model to national rates of CHD deaths per 
100,000, observed in the general population, as reported in the CDC WONDER22 database 
(ICD CODES I20-I25). We minimized the mean squared error, through an iterative series of 
informed guesses followed by a comparison of our model estimates to race-by-gender CHD 
deaths per 100,000 over the period of 2008-2018. This calibration ensured that CHD risk 
factors in our synthetic population predicted CHD mortality rates in a manner consistent with 
actual US CHD mortality rates. This process was particularly important given that the baseline 
CHD mortality estimates from the ARIC cohort, that we used to parameterize our simulations, 
were derived between 1996-1998.23  
 
Model Scenarios 
1. No Intervention  
2. Statins Intervention (2 levels: moderate uptake and strong uptake, among those with at least   
    1 CHD risk factor and >10% ten-year CHD risk)  
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3. Tobacco Tax Intervention ($2, $3 additional federal tax over 2 years) 
4. Education Intervention (increasing the proportion of black non-Hispanic Americans to match  
    that of their white non-Hispanic counterparts, for men and women separately) 
 
Technical Details 
The model was implemented in Microsoft Visual Studio 2012 (Microsoft Corp) and developed 
using C++. To account for stochasticity in the modeling process, each model scenario was run 
50 times, with mean statistical effect measures reported. The overview, design concept, and 
details protocol for this agent-based model is outlined in the Appendix 3, and provides an 
overview of the model and submodels, pseudocode, and an elaboration of design concepts 
and model details. We computed the 2.5th percentile and 97.5th percentile calculated across 
those 50 simulations, but do not present credible intervals because they did not differ from 
point estimates by more than 1/10th of a percent.  
 
Key Model Assumptions 
Our key model assumptions were that (1) our data inputs were representative of intervention 
effects that would be experienced by the United States population, (2) CHD Deaths were 
randomly distributed over the 10-year follow-up prediction period, and (3) that observed risk 
factors continued at their post-intervention or no-intervention levels into the future. The central 






Table 4.2 shows the characteristics of our simulated cohort of white non-Hispanic men 
(N=28,572,226), black non-Hispanic men (N=4,474,334), white non-Hispanic women 
(N=29,412,496), and black non-Hispanic women (N=5,182,602), without any intervention, and 
after each simulated intervention.  
 
Table 4.3 shows annualized fatal CHD risk before any intervention and after each simulated 
intervention. Among men, the annualized fatal CHD risk per 100,000, without any intervention, 
was 140.3 for all men, 134.9 for white non-Hispanic men, and 175.4 for black non-Hispanic 
men. Among women, the annualized fatal CHD risk per 100,000 without any intervention was 
47.5 for all women, 41.6 for white non-Hispanic women, 80.8 for black non-Hispanic women.  
 
Table 4.4 shows rate ratios and rate differences for men and women, comparing differences 
and ratios for simulated interventions compared to no intervention. Among men overall, the 
greatest rate reduction was seen for the strong uptake statins intervention [Rate Ratio 
(RR)=0.92], while among women overall, the strongest rate reduction was seen for the $3 tax 
(RR=0.96). The strong uptake statins intervention was associated with the strongest reduction 
in fatal CHD for white non-Hispanics (RR=0.92), while the strong uptake statins intervention was 
associated with the greatest reductions among black non-Hispanic men (RR=0.93); taxes were 
harmful to black non-Hispanic men [$2 tax (RR=1.05); $3 tax (RR=1.08)]. Effects on the rate 
difference scale were similar in ordering and magnitude across gender and race-by-gender 
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categories. Notably, large absolute increases in rate of annualized CHD deaths were observed 
among black non-Hispanic men for $2 (Rate Difference [RD]=+9.3 per 100,000) and $3 tax 
(RD=+13.9 per 100,000) interventions.    
 
Table 4.5 shows Differences in Differences and Ratios of Ratios, illustrating absolute and 
relative disparities in CHD mortality comparing no-intervention to tobacco taxes, statins, and 
education interventions. Among men, education was associated with the greatest absolute 
reduction (-7.6 CHD deaths per 100,000) in black-white disparities, compared to no 
intervention, while $2 and $3 tobacco taxes were associated with large absolute increases in 
black-white disparities (+11.5 and +17.3 CHD deaths per 100,000). In contrast, among women, 
the $3 tobacco tax was associated with the greatest absolute decrease (-4.3 CHD deaths per 
100,000). Ratio of ratio (RoR) estimates also demonstrated that among men education 
interventions reduced black-white disparities in CHD mortality (RoR=0.96), while $2 and $3 
tobacco taxes increased disparities in CHD mortality (RoR=1.07; RoR=1.11). Among women, 
the $3 tobacco tax intervention was associated with the strongest decrease in relative racial 
disparities (RoR=0.96), followed by strong uptake statins (RoR=-0.97) and education 
(RoR=0.98). Among men, education was the only intervention associated with relative 
decreases in racial disparities in CHD. Compared to strong uptake statins, $3 tobacco tax was 
associated with increases in absolute (RD=+18.2) and relative (RR=1.09) disparities for white 
and black non-Hispanic men, and was associated with decreases in absolute (RD=-1.0) and 
relative (RR=0.99) disparities for white and black non-Hispanic women.  
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Table 4.6 shows Years of Life Lost averted across intervention contrasts, comparing each 
intervention to no intervention, and then each tax intervention to weak uptake and strong 
uptake statins respectively. For men overall, each tax and statins intervention resulted in YLLs 
averted, compared to no intervention, with the greatest gains seen for the strong uptake 
statins intervention (777 per 100,000). For women overall, each intervention was associated 
with increases in YLLs averted, with the greatest gains seen for the $3 tobacco tax (287 per 
100,000). Among white non-Hispanic men, increases in YLLs averted, compared to no 
intervention, were seen for the $2 tax (253 per 100,000) and $3 tax (374 per 100,000), while for 
black non-Hispanic men decreases in YLLs averted were seen for the $2 tax (-633 per 100,000) 
and the $3 tax (-933 per 100,000). Increases in YLLs averted under statins were greater for 
white non-Hispanic men (weak uptake, 609 per 100,000; strong uptake, 1,042 per 100,000) 
than black non-Hispanic men (weak uptake, 348 per 100,000; strong uptake, 605 per 100,000). 
In contrast, YLLs averted under statins were greater for black non-Hispanic women weak 
uptake, 276 per 100,000; strong uptake, 466 per 100,000) than white non-Hispanic women 
(weak, 92 per 100,000; $3 tax, 147 per 100,000). Comparing taxation scenarios to statins 
scenarios, we can see that for men, taxation scenarios result in fewer YLLs averted per 100,000. 
In contrast, among women, taxation scenarios result in greater YLLs averted, with the exception 
of $2 tobacco taxes compared to strong uptake statins, which resulted in slightly fewer YLLs 
averted.  
    
Table 4.7 shows absolute total intervention costs, and costs per person for the statins 
interventions. Among men overall, weak uptake statins cost $8.6 billion ($260 per person) while 
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strong uptake statins cost $10.6 billion ($322 per person). Among women overall, weak uptake 
statins cost $5.6 billion ($161 per person), while strong uptake statins cost $6.2 billion ($171 
per person). Costs per person were higher among white compared to black non-Hispanic men, 
and higher among black compared to white non-Hispanic women.  
 
Figures 4.1a and 4.1b show the equity-effectiveness planes for comparison of YLLs averted by 
relative changes in racial disparities in CHD for men and women, comparing $2 taxation (1a) 
and $3 taxation (1b) to the statin interventions. Figures 4.2a and 4.2b show the equity 
effectiveness planes for comparison YLLs averted by absolute changes in racial disparities in 
CHD for men and women, comparing $2 taxation (4.1a) and $3 taxation (4.1b) to the statin 
interventions. For men, a $2 tax is a lose-lose intervention compared to statins (figure 4.1a), 
while a $3 tax is an efficiency win and equity lose compared to weak uptake statins, but a lose-
lose compared to strong uptake statins (figure 4.1b); absolute changes follow the same 
pattern, as shown in figures 4.2a and 4.2b. For women, a $2 tax is a win-win intervention 
compared to weak uptake statins, but does not depart from equity or efficiency measures 
compared to strong uptake statins, while a $3 tax is win-win compared to weak uptake and 









This simulation study shows that among men, compared to no intervention, an education 
intervention was associated with the greatest reduction in racial disparities in CHD mortality 
(RoR=0.96; DID=-7.6 per 100,000), while among women, a $3 tobacco tax intervention was 
associated with the greatest reduction in racial disparities in CHD mortality (RoR=0.96; DID=-
4.3 per 100,000). Among men, tobacco taxes increased racial disparities in CHD mortality 
(RoR=1.11; +17.3 CHD deaths per 100,000). For men overall, each tax and statins intervention 
resulted in YLLs averted, compared to no intervention, with the greatest gains seen for the 
strong statins intervention (777 per 100,000). For women overall, each intervention was 
associated with increases in YLLs averted, with the greatest gains seen for the $3 tobacco tax 
(287 per 100,000). Examining equity and effectiveness dimensions together, and comparing 
statins and taxation interventions, we found that compared to statins, tobacco taxes were in 
each case an equity lose intervention for men, while for women tobacco taxes were nearly 
always a win-win intervention. Conversely, compared to tobacco taxes, statins are an equity  
win intervention for men, and a lose-lose intervention for women.  
 
This study offers several novel contributions to the study of EETs in health. First, we are not 
aware of other studies that have explicitly examined equity efficiency tradeoffs in racial 
disparities in CHD in the United States. Second, we included gender specific exposure inputs 
in our simulation of the effects of tobacco taxes on CHD mortality. Third, we identified gender 
differences in the EET profiles of candidate interventions.  
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Conflicting EET profiles of tobacco taxes compared to statins by gender are challenging to 
integrate from a decision-making or policy perspective. Nonetheless, while simulations like 
these may not provide direct guidance or deterministic recommendations, they can yield useful 
information on which interventions may be optimal, which may be harmful, and for whom. 
Additionally, it is worth noting that while we modeled the effects of single interventions alone 
in the context of our simulations, in the “real world,” multiple interventions are often delivered 
at once, and structural interventions like tobacco taxation cannot be imposed differently based 
on gender. In addition, results suggesting harms from structural interventions like tobacco 
taxation may provide motivation to learn how to mechanistically counteract those harms. For 
example, if emergent black markets drive increases in smoking prevalence among black non-
Hispanic men following increases in tobacco taxation, improved regulatory control may reduce 
this source of harm and change the EET profile of tobacco taxation for men. A more expanded 
simulation could even integrate industry regulation and black-market control efforts.  
 
If resources for intervention were unlimited, then an aspirational approach to controlling CHD 
mortality nationwide could attempt to enact both high risk (e.g. statins) and population (e.g. 
tobacco taxes) approaches, while making efforts to minimize iatrogenic effects of tobacco 
taxation on black men. Under greater resource constraints, it could make sense to take the 
population approach of tobacco taxation while focusing the high-risk approach of statins on 
black non-Hispanic men, for example. Notably, while our simulation was conducted on a 
national level, policy decisions are typically made with respect to smaller areas, such as states, 
cities, or insurance catchments - each with their own unique set of needs and characteristics. 
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Accordingly, it is useful to be able to model the effects of a variety of interventions that target 
different disease mechanisms, as we have done here, in order to identify approaches that 
maximize equity and efficiency.  
 
Prior studies on EETs in CHD are few, but mostly consistent with our findings. One prior 
simulation examined EETs with a focus on CVD and economic inequities, and comparing 
universal screening approaches to universal screening plus structural interventions. Kypridemos 
and colleagues24 simulated the future cost effectiveness and equity of the UK’s National Health 
Service (NHS) Health Check alone, which is a high-risk approach that screens individuals for 
CVD risk and intervenes on identified risk factors, compared to the NHS health check plus a set 
of structural interventions that reduced tobacco use through regulation and increased fruit and 
vegetable consumption. They found that while optimal implementation of the NHS Health 
Check was cost-effective, it did not increase equity of future CVD cases across quintiles of 
income, while adding structural interventions to the NHS health Check is cost-saving and 
substantially increases equity of future CVD cases across income quintiles. They did not 
estimate the effects of structural interventions alone, but it is clear from their results that 
structural interventions drive the preponderance of effect of the combined treatments. While 
they did not estimate gender-specific effects, their results are consistent with our findings 
among women, who benefitted more from tobacco taxes than a high-risk statins intervention. 
Lu and colleagues examined interventions aimed at reducing inequities in CVD between white 
and black non-Hispanic Americans, but did not include an efficiency lens in addition to their 
equity analyses.10  They found that among both men and women, high-risk interventions on 
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dyslipidemia, hypertension and smoking cessation, based on a >2.5% cutoff for 10-year risk of 
fatal CVD, were more effective in reducing racial disparities in fatal CVD among black and 
white Americans than population wide interventions such as regulatory restriction of sodium in 
processed foods, comprehensive tobacco control including taxation, and price increases in 
sugar sweetened beverages.10 The finding for men was consistent with our findings, in that our 
high-risk strategy of statins intervention based on multiple-risk-factor scoring reduced 
disparities in CHD mortality, while tobacco taxation increased disparities.  
 
There are several ways in which our results are inconsistent with prior findings that are worth 
noting. First, in the study by Kypridemos and colleagues,24 structural interventions were more 
effective in reducing inequities than high risk interventions – this does not apply to our findings 
among men, for whom racial inequities were increased by a statins intervention. However, their 
findings are more relevant to economic than racial disparities and thus not necessarily in 
conflict with ours. The study by Lu and colleagues10 found that among women, statins alone are 
more effective in reducing inequalities in CVD than a tobacco tax intervention, contrary to our 
findings. However, the smoking intervention they modeled did not include race-specific, or 
race-by-gender specific estimates of the effects of smoking interventions on tobacco use, 
which our model included. Additionally, they used an intervention threshold of fatal CVD risk of 
> 2.5%, whereas we used a threshold of 10% risk of hard CHD. Finally, their statins alone 
intervention was not analogous to ours, as it was based on a treatment threshold of 




Our study does have several limitations that are worth noting. First, our study is a simulation 
and depends on the quality of our simulation and inputs. However, we created a simulation 
using an approximation of the United States that was built with demographic data from the 
ACS and PUMS, and risk factors from the nationally representative NHANES study, using a 
range of inputs derived from high-quality intervention estimates. Second, our smoking 
intervention model is based on smoking prevalence, a less detailed and sensitive measure than 
smoking frequency. Nonetheless, this is in some way a limitation of CHD risk prediction, and is 
not unique to our prediction models. Third, in our tobacco tax intervention, smokers who quit 
were reassigned CHD risk factors of non-smokers rather than former smokers, which would be 
more appropriate. However, we conducted a sensitivity analysis examining the effect of the 
smoking intervention absent a reassignment of other CHD risk factors, and found that our 
estimates were not appreciably different. Fourth, we used a fatal CHD risk prediction score that 
was derived from European studies. Nonetheless, we calibrated our risk prediction under no 











Notwithstanding limitations, this simulation study showed that the equity-efficiency profile of 
population health interventions in the context of reducing racial disparities in CHD may vary by 
gender. Equalizing the distribution of education was the only intervention that reduced racial 
disparities among men, while each intervention we tested (taxes, statins, education) reduced 
racial disparities among women. Tobacco taxation was the most effective intervention in 
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4.6 Figures and tables 
Figure 4.1 - Equity effectiveness planes for relative changes in racial disparities in CHD 
mortality (Ratio of Rate Ratios; see table 6) for (a) $2 tobacco taxes compared to statins and (b) 
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Figure 4.2 - Equity effectiveness planes for absolute changes in racial in annualized disparities 
in CHD mortality (Difference in Rate differences; see table 6) for (a) $2 tobacco taxes compared 
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Table 4.1 – Model Input Parameters 
Input Value Source 
Cost - moderate dose 
statins 
$78.17 per year 
Statins Medication - $48.00/year 
Lipid panel - $19.00/year 
Liver Panel - $1.17/year  
Physician Visit - $10.00/year 
Estimates are consistent with 
values used in recent simulation of 
primary prevention of CHD with 
statins.1   
Life expectancy by 
education (Years) 
White non-Hispanic men 
§ <High school: 72.0; >Some 
college: 78.2 
Black non-Hispanic men 
§ <High school: 65.2; >Some 
college: 72.3 
White non-Hispanic women 
§ <High school: 79.3; >Some 
college: 82.8 
Black non-Hispanic women 
§ <High school: 74.4; >Some 
college: 77.9 
Estimated by Meara and 
colleagues2 from Multiple Cause of 
Death Files and validated with the 
National Longitudinal Mortality 
Study.   
Fatal CHD 10-year Survival 
Rate 
White non-Hispanic men: 0.986 
Black non-Hispanic men: 0.972 
White non-Hispanic women: 0.995 
Black non-Hispanic women: 0.989 
Atherosclerosis Risk in 
Communities Study (ARIC)3  
Percentage point change in 
smoking prevalence per $1 
tobacco tax  
White non-Hispanic men: -0.4% 
Black non-Hispanic men: +1.1%  
White non-Hispanic women: -0.6% 
Black non-Hispanic women: -1.2% 
Estimated using the BRFSS4 and 
STATE System5  
Probability of Statins Uptake Estimated as a 300% increase - moderate 
uptake, and 500% increase – strong 
uptake, in the use of statins, stratified by 
race-gender, among those eligible for 
criteria similar to USPTF guidelines for 
primary prevention of Cardiovascular 
Disease.6   
300%, and 500% Increment in 
statin use among a synthetic 
population created using 
NHANES7 and the ACS8  
Percent biomarker change associated with moderate dose statins  
LDL cholesterol  -28.2% Calculated as the weighted 
average reduction in lipid levels 
from RCT trials on the benefits of 
statins among people without 
established CVD but with CVD risk 
factors9  






 Table 4.2 – Risk Profiles Pre- and Post-Intervention 




























Education (% Some college or more) 60.0% 62.2% 46.0% 64.1% 65.4% 56.4% 
Age (Mean)  54.62 54.69 54.21 54.67 54.73 54.32 
Total Cholesterol (Mean) 202.06 202.83 197.16 210.89 212.25 203.19 
HDL Cholesterol (Mean) 49.43 48.73 53.84 61.32 61.58 59.82 
Systolic Blood Pressure (Mean) 125.22 124.36 130.70 121.87 120.68 128.61 
% Smokers 23.4% 21.6% 34.8% 20.4% 19.9% 23.4% 
% Taking hypertension medication 24.9% 24.3% 29.3% 26.5% 23.6% 42.6% 
% Taking statins  22.6% 23.7% 15.7% 17.4% 17.3% 17.9% 














Post $2 Tobacco Tax Intervention 
Total Cholesterol (Mean) 201.84 202.49 197.71 210.38 211.81 202.30 
HDL Cholesterol (Mean) 49.44 48.72 54.00 61.29 61.57 59.69 
Systolic Blood Pressure (Mean) 125.23 124.31 131.11 121.79 120.64 128.36 
% Smokers 22.6% 20.0% 39.2% 17.6% 17.5% 18.6% 
Post $3 Tobacco Tax Intervention 
Total Cholesterol (Mean) 201.73 202.31 197.99 210.13 211.59 201.86 
HDL Cholesterol (Mean) 49.44 48.72 54.08 61.28 61.57 59.62 
Systolic Blood Pressure (Mean) 125.23 124.28 131.31 121.76 120.62 128.23 
% Smokers 22.2% 19.2% 41.4% 16.3% 16.3% 16.2% 









Total Cholesterol (Mean) 196.84 197.50 192.64 209.32 210.97 199.96 
HDL Cholesterol (Mean) 49.57 48.88 54.00 61.37 61.62 59.94 
% Taking statin medication 34.0% 35.2% 26.7% 20.8% 20.0% 25.4% 














Strong Uptake Statins 
Total Cholesterol (Mean) 193.11 193.73 189.16 208.19 210.04 197.68 
HDL Cholesterol (Mean) 49.68 48.98 54.12 61.40 61.64 60.02 
% Taking statin medication 42.2% 43.3% 35.2% 23.2% 21.9% 30.7% 














Post Education Intervention 
Education (% Some college or more) 62.2% - 62.1% 65.3% - 65.0% 
Total Cholesterol (Mean) 202.10 - 197.46 210.87 - 203.01 
HDL Cholesterol (Mean) 49.32 - 53.07 61.33 - 59.91 
Systolic Blood Pressure (Mean) 125.14 - 130.12 121.83 - 128.34 
% Smokers 22.8% - 30.9% 20.2% - 22.0% 
% Taking hypertension medication 24.9 - 29.0% 26.5% - 42.8% 
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No Intervention 140.3 134.9 175.4 47.5 41.6 80.8 
$2 Tobacco Tax 139.7 132.6 184.6 46.1 40.1 77.0 
$3 Tobacco Tax 139.3 131.5 189.3 45.4 40.6 75.1 
Moderate Uptake Statins 134.0 128.5 168.8 46.6 41.0 78.3 
Strong Uptake Statins 129.4 124.1 163.7 45.9 40.5 76.5 











Table 4.4 – Rate Ratios and Rate Differences comparing tobacco taxation, statins, and education intervention to no intervention 
within population on annualized fatal coronary heart disease per 100,000 
 
Intervention 
























Rate Ratios  
No Intervention 1 1 1 1 1 1 
$2 Tobacco Tax 1.00 0.98 1.05 0.97 0.98 0.95 
$3 Tobacco Tax 0.99 0.97 1.08 0.96 0.96 0.93 
Moderate Uptake Statins 0.95 0.95 0.96 0.98 0.98 0.97 
Strong Uptake Statins 0.92 0.92 0.93 0.97 0.97 0.95 
Education 0.99 - 0.96 0.99 - 0.98 
Rate Differences 
No Intervention - - - - - - 
$2 Tobacco Tax -0.7 -2.2 9.3 -1.4 -1.0 -3.8 
$3 Tobacco Tax -1.0 -3.4 13.9 -2.1 -1.5 -5.7 
Moderate Uptake Statins -6.4 -6.3 -6.6 -0.9 -0.6 -2.6 
Strong Uptake Statins -10.9 -10.8 -11.7 -1.6 -1.1 -4.4 








Table 4.5 – Ratio of Ratios and Differences in Differences comparing changes in racial disparities in annualized fatal CHD rates per 
100,000 under no-intervention compared to taxation, statins and education intervention, and taxation compared to statins 
interventions.  
 
 Difference in Differences* Ratio of Ratios** 
Intervention 
















No intervention reference group  
$2 Tobacco Tax 11.5 -2.9 1.07 0.98 
$3 Tobacco Tax 17.3 -4.3 1.11 0.96 
Moderate Uptake Statins -0.3 -1.9 1.01 0.98 
Strong Uptake Statins -0.9 -3.2 1.01 0.97 
Education -7.6 -1.6 0.96 0.98 
Moderate Uptake Statins reference group 
$2 Tobacco Tax 11.8 -0.9 1.06 0.99 
$3 Tobacco Tax 17.6 -2.4 1.10 0.98 
Strong Uptake Statins reference group 
$2 Tobacco Tax 12.4 0.4 1.06 1 
$3 Tobacco Tax 18.2 -1.0 1.09 0.99 
 
*Difference in differences = RDBNH - WNH Post – RDBNH/WNH Pre; negative numbers indicate decreases in disparities for black compared to 
white non-Hispanic persons, positive numbers indicate increases in disparities  
**Ratio of ratios = (RRBNH/WNH Post)/ (RRBNH/WNH Pre) for each intervention; number less than 1 represent decreases in disparities for black 





Table 4.6 – Years of Life Lost Averted by over the 10-year follow-up period 
Intervention 
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Table 4.7 – Statin Intervention Costs Over the 10-year period 
Intervention 
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Chapter 5: Conclusion 
  
Long-standing racial gaps in CHD mortality have continued into the 21st century. A tremendous 
amount of scientific work has focused on trying to understand and explain the root causes of 
these racial inequities, while comparatively less attention has been paid to understanding the 
effects of interventions focused on reducing these gaps. This dissertation provides an 
illustrative study of equity efficiency tradeoffs in fatal CHD, comparing black non-Hispanic to 
white non-Hispanic Americans. First, we conducted a scoping literature review of equity, 
efficiency and their tradeoffs across CVDs, identifying and summarizing prior work on EETs 
within this area. Second, we provided evidence on the race-gender specific effects of changes 
in tobacco taxation on smoking prevalence and CHD mortality. Third, we performed agent-
based microsimulations to study the effects of taxation ($2 and $3 tobacco tax), pharmaceutical 
(Statins), and early education interventions on racial gaps in CHD mortality, examining equity 
efficiency tradeoffs between taxation and statins interventions. 
 
5.1 Dissertation Findings  
Our scoping review of EETs in cardiovascular disease (Chapter 2) yielded a very small number 
of studies – only 6, that have explicitly engaged equity and efficiency, and provided 
information on their trade-offs in the context of CVDs broadly. This paucity of extant studies 
precludes the drawing of any clear and crosscutting conclusions about which types 
interventions are most likely to minimize tradeoffs between equity and efficiency. Nonetheless, 
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the empirical studies we identified demonstrated 2 important lessons. First, movement toward 
equity in the context of high-risk interventions may be achieved by specially targeting deprived 
populations. Second, pairing structural interventions with high risk interventions can provide 
substantial movement toward not only efficiency, but also equity. We identified a small but 
emergent field of scientific investigation into EETs in CVDs. Notably, all identified empirical 
studies were simulations, and future research could benefit the field by providing experimental 
and quasi-experimental observational data. Much work remains in the effort to integrate 
considerations of equity and EETs into evaluations of population health interventions on CVD. 
 
Our nationally representative observational, state-level, panel study of the effects of tobacco 
taxation on smoking prevalence and CHD mortality by race and gender (Chapter 3) identified 
clear effects for both outcomes and heterogeneous effects on smoking prevalence. We 
showed that between 2005 and 2016, tobacco taxation was associated with reductions in age-
adjusted smoking prevalence 1 year later, for white non-Hispanic men and women and black 
non-Hispanic women, and increases in smoking prevalence among black non-Hispanic men. 
Tobacco taxes were also associated with reductions in the rate of CHD mortality 2 years later.  
Taxation effects across race-ethnicity and gender were heterogeneous for changes in smoking 
prevalence and homogeneous for changes in CHD mortality. The strongest reductions in 
smoking prevalence were observed among black non-Hispanic women, while a potential 
increase was observed among black non-Hispanic men. Tobacco taxation appears to be an 
effective population health intervention on cigarette smoking prevalence and coronary heart 




Our simulation study (Chapter 4) shows that among men, compared to no intervention, an 
education intervention was associated with the greatest reduction in racial disparities in CHD 
mortality, while among women, a $3 tobacco tax intervention was associated with the greatest 
reduction in racial disparities in CHD mortality. Among men, tobacco taxes increased racial 
disparities in CHD mortality. For men overall, each tax and statins intervention resulted in 
reductions in YLLs to CHD mortality, compared to no intervention, with the greatest gains seen 
for the strong statins intervention. For women overall, each intervention was associated with 
reductions in YLLs due to CHD mortality, with the greatest gains seen for the $3 tobacco tax. 
Examining equity and effectiveness dimensions together, and comparing statins and taxation 
interventions, we found that compared to statins, tobacco taxes were an equity lose in all cases 
for men. For women, in contrast, tobacco taxes were nearly always a win-win intervention. 
Conversely, compared to tobacco taxes, statins are an equity win intervention for men, and a 
lose-lose intervention for women. Overall, we showed in this simulation study, that the equity-
efficiency profile of population health interventions in the context of reducing racial disparities 
in CHD may vary by gender. Among men, equalizing the distribution of education was the only 
intervention that reduced racial disparities, while among women, each intervention we tested 
(taxes, statins, education) reduced racial disparities. Tobacco taxation was the most effective 




5.2 Public health policy implications and future directions 
The key public health policy implication of this work is that the effectiveness, and racial equity 
effects of population health interventions are heterogeneous by gender. By extension, EETs 
likely differ by gender. That heterogeneity should be embraced in work that aims to reduce 
racial inequities in CHD mortality and work that examines EETs to that end.   
 
Another public health policy implication is that tobacco taxes are an effective policy lever for 
reducing CHD mortality. Prior studies have suggested this, but we convincingly identified these 
associations in a detailed and recent set of nationally representative data. Nonetheless, we 
need to be careful in considering the unintended consequences that can come with increases 
in tobacco taxation, including the potential for increases in smoking among populations that 
are particularly vulnerable to the targeting efforts of the tobacco companies. Further, it is 
imperative that we characterize and understand the race and gender specific effects of other 
policy levers that impact CHD, such as soda taxes and early education interventions like Head 
Start.  
 
An overarching theme of this work is the strength and utility of EET approaches to evaluating 
putative population health interventions aimed at reducing racial inequities in health. Despite 
the promise of this approach, it has been underutilized in the public health literature on 
socioeconomic inequities in CHD, and essentially unutilized in the literature on racial 




Our studies suggest several future directions for researchers. First these studies highlight the 
need for much additional scientific work in the efforts to understand population health 
intervention strategies that optimally maximize equity and efficiency in CHD, and CVD more 
broadly. This work could benefit greatly from explicit formulations of EETs. Second, the field 
would benefit from the examination of racial and ethnic inequities in CHD health care, in order 
to understand their influence on inequities in CHD health and mortality. Third, future research 
could productively give more focus to non-healthcare-based interventions (e.g. taxation, 
education) that have effects on CHD. Fourth, the effects of tobacco taxes on smoking behavior 
and CHD should be further examined by age, income and education groups, in order to more 
broadly understand the dynamics of this ongoing population health intervention on various 
equity dimensions. Finally, future studies on EETs in CHD could productively examine CHD 






























































































































































































































































































































































































































































































Appendix Table 2.1 – Search Terms  
Database Name Hits Search Query 
Embase 663 ('cardiovascular disease'/exp OR 'cardiovascular' OR 'coronary' OR 'myocardial' 
OR 'heart' OR 'cardiac' OR 'stroke' OR 'strokes' OR 'apoplexy' OR 
'cardiomyopathy' OR 'cerebrovascular' OR 'vascular' OR 'blood vessel' OR 'blood 
vessels' OR 'pericardium') AND ('health equity'/exp OR 'health care disparity'/exp 
OR 'health disparity'/exp OR 'equity' OR 'equitable' OR 'parity' OR 'equality' OR 
'disparity' OR 'disparities' OR 'inequity' OR 'inequitable' OR 'inequities' OR 
'inequality') AND ('productivity'/exp OR 'efficiency' OR 'efficient' OR 'efficiently' 
OR 'inefficiency' OR 'inefficient' OR 'inefficiently' OR 'productivity' OR 'productive' 
OR 'productively' OR 'nonproductive' OR 'unproductive' OR 'counterproductive' 
OR 'efficacy' OR 'efficaciously' OR 'efficaciousness' OR 'inefficacy' OR 
'inefficaciously' OR 'inefficaciousness' OR 'effective' OR 'effectiveness' OR 
'effectively' OR 'ineffective' OR 'ineffectiveness' OR 'ineffectively' OR 'ineffectual' 
OR 'ineffectually') AND ('cost benefit analysis'/exp OR 'cost effectiveness 
analysis'/exp OR 'trade-off' OR 'trade-offs' OR 'tradeoff' OR 'tradeoffs' OR 
'trading off' OR 'Cost Benefit' OR 'Cost-Benefits' OR 'Costs-Benefit' OR 'Costs-
Benefits' OR 'Cost-Effect' OR 'Cost Effects' OR 'Costs-Effect' OR 'Costs-Effects' 
OR 'Cost-Utility' OR 'Economic Evaluation' OR 'Economic Evaluations' OR 
'Marginal Analysis' OR 'Marginal Analyses' OR 'Cost and Benefit' OR 'Costs and 
Benefit' OR 'Cost and Benefits' OR 'Costs and Benefits' OR 'Benefit and Cost' OR 
'Benefits and Cost' OR 'Benefit and Costs' OR 'Benefits and Costs' OR 'Cost and 
Effect' OR 'Costs and Effect' OR 'Cost and Effects' OR 'Costs and Effects' OR 
'Effect and Cost' OR 'Effects and Cost' OR 'Effect and Costs' OR 'Effects and 
Costs' OR 'cost-efficiency' OR 'cost-efficient' OR 'cost-efficiently' OR 'cost-
inefficiency' OR 'cost-inefficient' OR 'cost-inefficiently' OR 'cost productivity' OR 
'cost-productive' OR 'cost-productively' OR 'cost-nonproductive' OR 'cost-
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unproductive' OR 'cost-counterproductive' OR 'cost-efficacy' OR 'cost-
efficaciously' OR 'cost-efficaciousness' OR 'cost-inefficacy' OR 'cost-inefficaciously' 
OR 'cost-inefficaciousness' OR 'cost-effective' OR 'cost effectiveness' OR 'cost-
effectively' OR 'cost-ineffective' OR 'cost-ineffectiveness' OR 'cost ineffectively' 
OR 'cost-ineffectual' OR 'cost-ineffectually')  
Pubmed 217 ("Cardiovascular Diseases"[Mesh] OR “cardiovascular”[tw] OR “coronary”[tw] OR 
“myocardial”[tw] OR “heart”[tw] OR “cardiac”[tw] OR “stroke”[tw] OR 
“strokes”[tw] OR “apoplexy”[tw] OR “cardiomyopathy”[tw] OR 
“cerebrovascular”[tw] OR “vascular”[tw] OR “blood vessel”[tw] OR “blood 
vessels”[tw] OR “pericardium”[tw]) AND ("Health Equity"[Mesh] OR "Healthcare 
Disparities"[Mesh] OR "Health Status Disparities"[Mesh] OR “equity”[tw] OR 
“equitable”[tw] OR “parity”[tw] OR “equality”[tw] OR “disparity”[tw] OR 
“disparities”[tw] OR “inequity”[tw] OR “inequitable”[tw] OR “inequities”[tw] OR 
“inequality”[tw]) AND ("Efficiency"[Mesh] OR “efficiency”[tw] OR “efficient”[tw] 
OR “efficiently”[tw] OR “inefficiency”[tw] OR “inefficient”[tw] OR 
“inefficiently”[tw] OR “productivity”[tw] OR “productive”[tw] OR 
“productively”[tw] OR “nonproductive”[tw] OR “unproductive”[tw] OR 
“counterproductive”[tw] OR “efficacy”[tw] OR “efficaciously”[tw] OR 
“efficaciousness”[tw] OR “inefficacy”[tw] OR “inefficaciously”[tw] OR 
“inefficaciousness”[tw] OR “effective”[tw] OR “effectiveness”[tw] OR 
“effectively”[tw] OR “ineffective”[tw] OR “ineffectiveness”[tw] OR 
“ineffectively”[tw] OR “ineffectual”[tw] OR “ineffectually”[tw]) AND ("Cost-Benefit 
Analysis"[Mesh] OR “trade-off”[tw] OR “trade-offs”[tw] OR “tradeoff”[tw] OR 
“tradeoffs”[tw] OR “trading off”[tw] OR "Cost-Benefit"[tw] OR "Cost-Benefits"[tw] 
OR "Costs-Benefit"[tw] OR "Costs-Benefits"[tw] OR “Cost-Effect”[tw] OR “Cost-
Effects”[tw] OR “Costs-Effect”[tw] OR “Costs-Effects”[tw] OR "Cost-Utility”[tw] OR 
"Economic Evaluation"[tw] OR "Economic Evaluations"[tw] OR "Marginal 
Analysis"[tw] OR "Marginal Analyses"[tw] OR “Cost and Benefit”[tw] OR “Costs 
and Benefit”[tw] OR “Cost and Benefits”[tw] OR "Costs and Benefits"[tw] OR 
“Benefit and Cost”[tw] OR “Benefits and Cost”[tw] OR “Benefit and Costs”[tw] 
OR "Benefits and Costs"[tw] OR “Cost and Effect”[tw] OR “Costs and Effect”[tw] 
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OR “Cost and Effects”[tw] OR "Costs and Effects"[tw] OR “Effect and Cost”[tw] 
OR “Effects and Cost”[tw] OR “Effect and Costs”[tw] OR "Effects and Costs"[tw] 
OR “cost-efficiency”[tw] OR “cost efficient”[tw] OR “cost-efficiently”[tw] OR “cost-
inefficiency”[tw] OR “cost-inefficient”[tw] OR “cost-inefficiently”[tw] OR “cost-
productivity”[tw] OR “cost-productive”[tw] OR “cost-productively”[tw] OR “cost-
nonproductive”[tw] OR “cost-unproductive”[tw] OR “cost counterproductive”[tw] 
OR “cost-efficacy”[tw] OR “cost-efficaciously”[tw] OR “cost efficaciousness”[tw] 
OR “cost-inefficacy”[tw] OR “cost-inefficaciously”[tw] OR “cost 
inefficaciousness”[tw] OR “cost-effective”[tw] OR “cost-effectiveness”[tw] OR 
“cost effectively”[tw] OR “cost-ineffective”[tw] OR “cost-ineffectiveness”[tw] OR 




Web of Science 276 TS=("cardiovascular" OR "coronary" OR "myocardial" OR "heart" OR "cardiac" 
OR "stroke" OR "strokes" OR "apoplexy" OR "cardiomyopathy" OR 
"cerebrovascular" OR "vascular" OR "blood vessel" OR "blood vessels" OR 
"pericardium") AND TS=("equity" OR "equitable" OR "parity" OR "equality" OR 
"disparity" OR "disparities" OR "inequity" OR "inequitable" OR "inequities" OR 
"inequality") AND TS=("efficiency" OR "efficient" OR "efficiently" OR 
"inefficiency" OR "inefficient" OR "inefficiently" OR "productivity" OR 
"productive" OR "productively" OR "nonproductive" OR "unproductive" OR 
"counterproductive" OR "efficacy" OR "efficaciously" OR "efficaciousness" OR 
"inefficacy" OR "inefficaciously" OR "inefficaciousness" OR "effective" OR 
"effectiveness" OR "effectively" OR "ineffective" OR "ineffectiveness" OR 
"ineffectively" OR "ineffectual" OR "ineffectually") AND TS=("trade-off" OR 
"trade-offs" OR "tradeoff" OR "tradeoffs" OR "trading off" OR "Cost-Benefit" 
OR "Cost-Benefits" OR "Costs-Benefit" OR "Costs-Benefits" OR "Cost-Effect" 
OR "Cost-Effects" OR "Costs-Effect" OR "Costs-Effects" OR "Cost-Utility" OR 
"Economic Evaluation" OR "Economic Evaluations" OR "Marginal Analysis" OR 
"Marginal Analyses" OR "Cost and Benefit" OR "Costs and Benefit" OR "Cost 
and Benefits" OR "Costs and Benefits" OR "Benefit and Cost" OR "Benefits and 
Cost" OR "Benefit and Costs" OR "Benefits and Costs" OR "Cost and Effect" OR 
"Costs and Effect" OR "Cost and Effects" OR "Costs and Effects" OR "Effect and 
Cost" OR "Effects and Cost" OR "Effect and Costs" OR "Effects and Costs" OR 
"cost-efficiency" OR "cost-efficient" OR "cost-efficiently" OR "cost-inefficiency" 
OR "cost-inefficient" OR "cost-inefficiently" OR "cost-productivity" OR "cost 
productive" OR "cost-productively" OR "cost-nonproductive" OR "cost-
unproductive" OR "cost counterproductive" OR "cost-efficacy" OR "cost-
efficaciously" OR "cost-efficaciousness" OR "cost-inefficacy" OR "cost-
inefficaciously" OR "cost-inefficaciousness" OR "cost-effective" OR "cost-
effectiveness" OR "cost-effectively" OR "cost-ineffective" OR "cost-





Business Source Complete 20 ("cardiovascular" OR "coronary" OR "myocardial" OR "heart" OR "cardiac" OR 
"stroke" OR "strokes" OR "apoplexy" OR "cardiomyopathy" OR 
"cerebrovascular" OR "vascular" OR "blood vessel" OR "blood vessels" OR 
"pericardium") AND ("equity" OR "equitable" OR "parity" OR "equality" OR 
"disparity" OR "disparities" OR "inequity" OR "inequitable" OR "inequities" OR 
"inequality") AND ("efficiency" OR "efficient" OR "efficiently" OR "inefficiency" 
OR "inefficient" OR "inefficiently" OR "productivity" OR "productive" OR 
"productively" OR "nonproductive" OR "unproductive" OR "counterproductive" 
OR "efficacy" OR "efficaciously" OR "efficaciousness" OR "inefficacy" OR 
"inefficaciously" OR "inefficaciousness" OR "effective" OR "effectiveness" OR 
"effectively" OR "ineffective" OR "ineffectiveness" OR "ineffectively" OR 
"ineffectual" OR "ineffectually") AND ("trade-off" OR "trade-offs" OR "tradeoff" 
OR "tradeoffs" OR "trading off" OR "Cost-Benefit" OR "Cost-Benefits" OR 
"Costs-Benefit" OR "Costs-Benefits" OR "Cost-Effect" OR "Cost-Effects" OR 
"Costs-Effect" OR "Costs-Effects" OR "Cost-Utility" OR "Economic Evaluation" 
OR "Economic Evaluations" OR "Marginal Analysis" OR "Marginal Analyses" OR 
"Cost and Benefit" OR "Costs and Benefit" OR "Cost and Benefits" OR "Costs 
and Benefits" OR "Benefit and Cost" OR "Benefits and Cost" OR "Benefit and 
Costs" OR "Benefits and Costs" OR "Cost and Effect" OR "Costs and Effect" OR 
"Cost and Effects" OR "Costs and Effects" OR "Effect and Cost" OR "Effects and 
Cost" OR "Effect and Costs" OR "Effects and Costs" OR "cost efficiency" OR 
"cost-efficient" OR "cost-efficiently" OR "cost-inefficiency" OR "cost-inefficient" 
OR "cost-inefficiently" OR "cost-productivity" OR "cost-productive" OR "cost-
productively" OR "cost-nonproductive" OR "cost-unproductive" OR "cost-
counterproductive" OR "cost-efficacy" OR "cost-efficaciously" OR "cost-
efficaciousness" OR "cost-inefficacy" OR "cost-inefficaciously" OR "cost-
inefficaciousness" OR "cost-effective" OR "cost-effectiveness" OR "cost-
effectively" OR "cost-ineffective" OR "cost-ineffectiveness" OR "cost-




EconLit 16 ("cardiovascular" OR "coronary" OR "myocardial" OR "heart" OR "cardiac" OR 
"stroke" OR "strokes" OR "apoplexy" OR "cardiomyopathy" OR 
"cerebrovascular" OR "vascular" OR "blood vessel" OR "blood vessels" OR 
"pericardium") AND ("equity" OR "equitable" OR "parity" OR "equality" OR 
"disparity" OR "disparities" OR "inequity" OR "inequitable" OR "inequities" OR 
"inequality") AND ("efficiency" OR "efficient" OR "efficiently" OR "inefficiency" 
OR "inefficient" OR "inefficiently" OR "productivity" OR "productive" OR 
"productively" OR "nonproductive" OR "unproductive" OR "counterproductive" 
OR "efficacy" OR "efficaciously" OR "efficaciousness" OR "inefficacy" OR 
"inefficaciously" OR "inefficaciousness" OR "effective" OR "effectiveness" OR 
"effectively" OR "ineffective" OR "ineffectiveness" OR "ineffectively" OR 
"ineffectual" OR "ineffectually") AND ("trade-off" OR "trade-offs" OR "tradeoff" 
OR "tradeoffs" OR "trading off" OR "Cost-Benefit" OR "Cost-Benefits" OR 
"Costs-Benefit" OR "Costs-Benefits" OR "Cost-Effect" OR "Cost-Effects" OR 
"Costs-Effect" OR "Costs-Effects" OR "Cost-Utility" OR "Economic Evaluation" 
OR "Economic Evaluations" OR "Marginal Analysis" OR "Marginal Analyses" OR 
"Cost and Benefit" OR "Costs and Benefit" OR "Cost and Benefits" OR "Costs 
and Benefits" OR "Benefit and Cost" OR "Benefits and Cost" OR "Benefit and 
Costs" OR "Benefits and Costs" OR "Cost and Effect" OR "Costs and Effect" OR 
"Cost and Effects" OR "Costs and Effects" OR "Effect and Cost" OR "Effects and 
Cost" OR "Effect and Costs" OR "Effects and Costs" OR "cost efficiency" OR 
"cost-efficient" OR "cost-efficiently" OR "cost-inefficiency" OR "cost-inefficient" 
OR "cost-inefficiently" OR "cost-productivity" OR "cost-productive" OR "cost-
productively" OR "cost-nonproductive" OR "cost-unproductive" OR "cost-
counterproductive" OR "cost-efficacy" OR "cost-efficaciously" OR "cost-
efficaciousness" OR "cost-inefficacy" OR "cost-inefficaciously" OR "cost-
inefficaciousness" OR "cost-effective" OR "cost-effectiveness" OR "cost-
effectively" OR "cost-ineffective" OR "cost-ineffectiveness" OR "cost-
ineffectively" OR "cost-ineffectual" OR "cost-ineffectually")  




Appendix Figure 3.1 – Spaghetti plot of total combined state and federal tobacco tax by state: 2005-2016 
 










‡ weighted by each state-year by strata of race/ethnicity by gender with denominators from 
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Appendix Figure 3.3 – National estimates of real median per capita income by year‡ 
 
 
‡- weighted by each state-year by strata of race/ethnicity by gender with denominators from 
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Population Strata 2005 2006 2007 2008 
Overall   126,049,991   126,245,221   130,555,331     128,040,936     131,408,369    131,252,313    132,228,255     130,511,937  
Men     59,487,921     58,863,290     61,693,778       59,939,520       62,130,621      61,454,969      62,530,646       61,100,576  
Women     66,562,070     67,381,931     68,861,553       68,101,416       69,277,748      69,797,345      69,697,609       69,411,361  
White non-Hispanic   110,732,415   112,618,481   114,194,457     114,306,548     114,815,414    116,689,386    115,358,861     115,365,190  
Black non-Hispanic     15,317,576     13,626,740     16,360,874       13,734,388       16,592,955      14,562,927      16,869,394       15,146,747  
White Non-Hispanic     52,867,764     52,906,680     54,404,997       53,918,614       54,743,051      54,943,173      55,025,089       54,304,407  
Black Non-Hispanic       6,620,157       5,956,610       7,288,781         6,020,906         7,387,570        6,511,795        7,505,557         6,796,170  
   White Non-Hispanic       57,864,651     59,711,800     59,789,460       60,387,934       60,072,363      61,746,213      60,333,772       61,060,783  
Black Non-Hispanic       8,697,419       7,670,130       9,072,093         7,713,483         9,205,385        8,051,131        9,363,837         8,350,577  
Population Strata 2009 2010 2011 2012 
Overall   132,522,623   133,191,002   133,603,140     140,168,222     134,166,142    132,171,331    134,769,423     133,262,350  
Men     62,678,145     62,373,406     63,473,793       65,890,580       63,766,872      61,675,260      64,108,987       62,519,555  
Women     69,844,478     70,817,596     70,129,347       74,277,642       70,399,270      70,496,071      70,660,436       70,742,795  
White non-Hispanic   115,547,948   117,253,142   115,962,083     124,179,189     116,288,380    115,294,207    116,660,319     115,117,636  
Black non-Hispanic     16,974,675     15,937,861     17,641,057       15,989,033       17,877,762      16,877,124      18,109,104       18,144,714  
White Non-Hispanic     55,128,402     55,390,543     55,548,924       59,061,661       55,739,158      53,783,901      55,962,572       54,358,376  
Black Non-Hispanic       7,549,743       6,982,863       7,924,869         6,828,919         8,027,714        7,891,359        8,146,415         8,161,179  
White Non-Hispanic       60,419,546     61,862,599     60,413,159       65,117,528       60,549,222      61,510,306      60,697,747       60,759,260  












Population Strata 2013 2014 2015 2016 
Overall   135,400,531   133,675,453   136,109,097     135,162,186     136,927,291    136,219,583    137,498,260     136,386,981  
Men     64,424,307     62,846,540     64,798,023       63,610,466       65,218,025      64,221,449      65,506,678       64,310,837  
Women     70,976,224     70,828,913     71,311,074       71,551,720       71,709,266      71,998,133      71,991,582       72,076,144  
White non-Hispanic   117,048,811   115,054,316   117,383,827     116,186,311     117,878,239    116,908,616    118,265,212     116,926,836  
Black non-Hispanic     18,351,720     18,621,137     18,725,270       18,975,874       19,049,052      19,310,966      19,233,048       19,460,146  
White Non-Hispanic     56,191,739     54,439,114     56,384,435       54,945,386       56,652,651      55,312,607      56,861,441       55,533,255  
Black Non-Hispanic       8,232,568       8,407,426       8,413,588         8,665,079         8,565,374        8,908,842        8,645,237         8,777,583  
White Non-Hispanic       60,857,072     60,615,202     60,999,392       61,240,925       61,225,588      61,596,009      61,403,771       61,393,581  
Black Non-Hispanic     10,119,152     10,213,711     10,311,682       10,310,795       10,483,678      10,402,124      10,587,811       10,682,563  
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Appendix Table 3.2 – Effect per $1 of total tobacco tax, lagged by 1 year, on smoking prevalence among Americans ages 35 and 



























1,966 -0.4 -0.6 -0.2 
Log Pseudolikelihood= -624.95306     
AIC=0.6510204; BIC= -14790.82  - - 
Men 976 -0.1 -0.4 0.2 Log Pseudolikelihood= -624.6680841  
AIC= 0.6609034; BIC= -14715.55 
X2 (1) =  
6.83    
p=  
0.0090 Women 990 -0.6 -0.8 -0.4 
White non-Hispanic  1,122 -0.5 -0.8 -0.3 Log Pseudolikelihood= -624.185312  
AIC=0.6604123; BIC=-14716.52   
X2 (1) =  
0.96    
p=   
0.3262 Black non-Hispanic 844 -0.2 -0.9 0.4 
White non-Hispanic men 561 -0.4 -0.8 -0.1 
Log Pseudolikelihood= -623.800352   
AIC=0.6813839; BIC= -14558.03 




Black non-Hispanic men  415 1.2 -0.3 2.5 
White non-Hispanic women 561 -0.7 -0.9 -0.4 
Black non-Hispanic women 429 -1.2 -1.6 -0.8 
 
§ - multiplied by 100 for interpretation 







Appendix Table 3.3: Effect per $1 of total tobacco tax, lagged by 2 years, on number of Coronary Heart Disease Deaths among 





















-5 -9 -2 
Log Pseudolikelihood= -7090.53155 
AIC= 8.213331; BIC= -11043.36  - - 
Men 861 -6 -10 -3 Log Pseudolikelihood=-6802.28711   
AIC=7.890505; BIC= -11552.75   
X2 (1) 
=0.18    
p= 
0.6724 Women 869 -4 -6 -1 
White non-Hispanic  1020 -5 -8 -1 Log Pseudolikelihood=-6788.62884   
AIC=7.874715; BIC=-11580.06   
X2 (1) 
=1.71    
p= 
0.1912   Black non-Hispanic 710 -8 -11 -6 
White non-Hispanic men 510 -6 -10 -2 
Log Pseudolikelihood= -6465.10761   
AIC=7.522668; BIC=-12085.44  
X2(1)= 
5.67   
p= 
0.1287   
Black non-Hispanic men  351 -9 -13 -5 
White non-Hispanic women 510 -3 -6 0 
Black non-Hispanic women 359 -7 -9 -5 
 
*counts rounded to whole numbers  







Appendix Table 3.4 – Effect per $1 of total tobacco tax, lagged by 1 year, on smoking prevalence among Americans ages 35 and 



















Overall 1922 -0.4 -0.6 -0.2 R2= 0.7396, Root MSE= .02023 - - 
Men 909 -0.1 -0.5 0.3 
R2= 0.7688, Root MSE=.01938 
f(1,50 )=  
4.20  
p=  
0.0459  Women 1013 -0.6 -0.8 -0.3 
White non-Hispanic  1100 -0.5 -0.8 -0.2 
R2= 0.8180, Root MSE=.01714 
f(1,50 )= 
0.19   
p= 
0.6689 Black non-Hispanic 822 -0.3 -1.1 0.4 
White non-Hispanic men 550 -0.4 -0.8 0.0 
R2=0.8569, Root MSE=.01567   
f(3,50 )= 
8.94   
p=  
0.0001    
Black non-Hispanic men  404 1.1 -0.5 2.6 
White non-Hispanic women 550 -0.6 -0.9 -0.4 
Black non-Hispanic women 418 -1.2 -1.7 -0.8 
 
*Wisconsin and Wyoming excluded due to collinearity 
§ - multiplied by 100 for interpretation 








Appendix Table 3.5 – Effect per $1 of total tobacco tax, lagged by 2 years, on percent change in CHD deaths among Americans 



















Overall 1690 -2.0 -3.6 -0.3 R2= 0.9689, Root MSE=0.06776 - - 
Men 841 -2.0 -3.5 -0.6 
R2= 0.9810, Root MSE=0.05394 
f(1,50 )=  
0.14  
p=  
0.7059   Women 849 -1.9 -3.7 -0.1 
White non-Hispanic  1000 -1.8 -3.7 0.1 
R2= 0.9774, Root MSE=0.05861 
f(1,50 )= 
2.17   
p=  
0.1471 Black non-Hispanic 690 -3.4 -4.6 -2.2 
White non-Hispanic men 500 -1.8 -3.3 -0.2 
R2= 0.9904, Root MSE= 0.03947   
f(3,50 )= 
1.36   
p= 
 0.2664    
Black non-Hispanic men  341 -3.0 -4.7 -1.3 
White non-Hispanic women 500 -1.5 -3.5 0.6 
Black non-Hispanic women 349 -3.5 -4.9 -2.1 
 
*Wisconsin and Wyoming excluded due to collinearity 
§ - multiplied by 100 for interpretation 
























Overall 1,646 1.9 -1.1 4.8 R2= 0.9284, Root MSE=0.10958 - - 
Men 843 1.5 -2.0 4.9 




0.1470 Women 803 2.7 -0.2 5.6 
White non-Hispanic 1008 1.8 -1.4 5.0 




0.7082 Black non-Hispanic 668 0.9 -3.1 5.0 
White non-Hispanic men 505 1.0 -2.5 4.6 





Black non-Hispanic men 338 1.0 -2.6 4.5 
White non-Hispanic women 503 2.2 -0.9 5.4 
Black non-Hispanic women 300 1.3 -3.2 5.8 
§ - multiplied by 100 for interpretation
‡- weighted by each state-year by strata of race/ethnicity by gender with denominators from the American Community Survey
Appendix 4
The “Equity-Efficiency Tradeoffs (EET)” ABM is described in detail in accordance to ODD 
(Overview, Design concept and Details) protocol [1] as below:
1 Purpose
The purpose of this ABM is to simulate and compare the effects of statins, tobacco tax and 
early education interventions on CHD related mortality among white and black non-hispanic 
population in United States.
2 Entities, state variables and scales
The main entities of the model are agents with distinct sets of socio-demographic attributes 
(age, gender, race/ethnicity, income and educational attainment) and CHD related risk factors -
cholesterol level (HDL, LDL and total cholesterol), systolic blood pressure and smoking status.
3 Process overview and scheduling
The sub-models of this simulation for a given intervention are processed in following order:
(a) Compute 10-year risk of Fatal Coronary Heart Disease (CHD) before the intervention
(b) Execute intervention (Tobacco Tax or Statins or Early Education)
(c) Compute 10-year risk of Fatal Coronary Heart Disease (CHD) after the intervention
(d) Process Coronary Heart Disease (CHD) related deaths
4 Design concepts
This model includes several design concepts of agent-based models such as adaptive behavior,




Adaptive behavior can be defined as decisions that agents make to change their state, to pursue
some objectives, in response to current state of themselves and their environment [1].
In this model, agents have an ability to decide whether they want to -
(a) quit smoking after an increase in tobacco taxes.
(b) take statins to reduce cholesterol levels.
(c) attend college.
4.2 Stochasticity
Stochasticity presents randomness in our model which is used to execute agent behaviors such
as statins intake. For example, a random real number drawn between 0 and 1 is compared
against probability of statins intake to determine whether an agent uses statins to reduce his or
her cholesterol level.
4.3 Observation
Themain purpose of this design concept is to understand model behavior through numerical and
graphical displays. This ensures that agents are executing their behavioral rules as intended. In
this model, average of risk factors and 10-year risk of CHD (Coronary Heart Disease) mortality,
before and after the interventions, are evaluated.
5 Initialization
The initialization steps are described in detail below:
5.1 Create synthetic population
This section provides an overview of process involved in building a synthetic population of 50
US States and the District of Columbia. Our population model consists of lists of households
139
characterized by household type, size and income where each household has at least one person
(or agent) with distinct socio-demographic attributes such as age, gender, race and education.






Gender Male, Female 2015 ACS 5-Year Selected
Population Tables:
1. Sex by Age (Non-Hispanic
origin by Race)
2. Sex by Age (Hispanic origin by
Race)
Age 0-5, 5-9, 10-14, 15-17, 18-19, 20-
24, 25-29, 30-34, 35-44, 45-54, 55-
64, 65-74, 75-84, 85+
Ethnicity Not Hispanic or Latino, Hispanic or
Latino
Race White, Black or African American,
American Indian and Alaska Na-
tive, Native Hawaiian and Other Pa-
cific Islander, Other Race
Educational
attainment
Less than 9th grade, 9th to 12th grade
(no diploma), High school gradu-
ate, Some college (no degree), As-
sociate degree, Bachelor’s degree,
Graduate or professional degree.
2015 ACS 5-year estimates:
1. Sex by Age by Educational at-











b. Male householder, no wife
c. Female householder, no husband
Non Family Households
a. Householder living alone
b. Householder not living alone
2015 ACS 5-Year Selected
Population Tables:
1. Sex by Age (Non-Hispanic
origin by Race)




1 person, 2 person, 3 person, 4 per-
son, 5 person, 6 person, 7 or more
person
2015 ACS 5-years estimates:




1. Less than $10,000
2.$10,000 to $14,999
3. $15,000 to $24,999
4. $25,000 to $34,999
5. $35,000 to $49,999
6. $50,000 to $74,999
7. $75,000 to $99,999
8. $100,000 to $149,999
9. $150,000 to $199,999
10. $200,000 or more
2015 ACS Selected Population Ta-
bles
1. Household Income in the past 12




We’ve used an approach called Iterative Proportional Updating (IPU), developed by a group in
Arizona State University [2], which computes selection probabilities different household types
(cross-tabulation of households based on household type, size and income) by iteratively ad-
justing weights until both household-level and person-level estimates match joint distributions
(both household-level and person-level) obtained from IPF (Iterative Proportional Fitting) pro-
cedure. The steps detailing generation of synthetic population of states are described in sections
below:
5.1.4 Steps for synthetic population generation
Step 1: Create US states and import population estimates
States are categorized by a unique geo ID, name and population count. Each State consists of
list counties which are mapped to unique statistical geographical areas called PUMAs (Public
Use Microdata Area). A PUMA county crosswalk is used to establish a mapping between
respective counties and PUMA codes. After mapping states with counties, we import and assign
population (household and person-level) estimates from ACS to states based on its geo ID.
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Step 2: Import PUMS (Public Use Microdata Sample) file
PUMS file consist sample data of population and housing units collected through individual
ACS questionnaires. Each record in a population file represents a single person with distinct
attributes such as age, race, gender, educational attainment and so on. Similarly, each entry in
household-level dataset indicates a single housing unit which consists of at least on person. Each
housing unit is categorized by PUMA code indicating the area it belongs. Both person-level and
household-level PUMS dataset is available for 50 US states including District of Columbia.
Step 3: Estimate joint (person-level and household-leve) distributions using IPF
IPF is an iterative procedure of estimating the cell-values of contingency table until they add
up to selected totals for both row and column marginals. In our model, it has been used to
estimate the joint distributions of person level attributes stratified by sex, age category, race and
education and household-level stratified by household type, size and income.
Step 4: Compute weights for households
In Iterative Proportional Updating (IPU) approach, the weights assigned to each households are
iteratively adjusted until the cumulative sum of each household and person-types matches IPF
generated marginal distributions for households and persons. The process begins by creating a
frequency matrix M (Figure 1) from modified PUMS dataset.
Figure 1: An example of IPU approach [2]
A row in frequency matrix represents one household and the columns within a row are the fre-
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quencies of household-types and person-types extracted from PUMS dataset. Household types
are classified by stratifying household variables such as type (married-couple, single parent
etc.), size and income. Similarly, person-types are obtained by cross-classifying attributes such
as age, race, gender, educational attainment. The weights of all the households are initially set
to one as illustrated in Table 1 above. A row labeled “Weighted sum” is weighted sum of each
column and “Constraints” represents marginal frequencies of each column (household-types
and person-types) that must be matched. The weights of households are adjusted with respect
to each column representing household/person-type and are calculated as:




The rows labeled “Weighted sum 1” through “Weighted Sum 5” are the weighted sum of five
columns representing household and person types in Table 1. The weighted sum and constraints








i = row number representing each households (i = 1, 2,…, n)
j = household/person-type of interest (j = 1, 2, …., n)
dij = frequency of jth household/persons-type
wj = weight of ith household
cj = marginal distribution of jth household/person-type
The adjustment of weights through all the columns of frequency matrix marks the completion
of single iteration. The average of δj is calculated across all the columns, prior to and after
adjustment of weights, is denoted by δa and δb respectively. The difference between δa and δb
represents gain in fit (∆) between two consecutive iterations. The weights are adjusted until
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gain in fit (∆) reaches below a cut-off threshold (ε).
Step 5: Draw households
In this step, households are drawn probabilistically based on IPU estimates household weights.
The selection probabilities are calculated for each household type which are compared against
randomly generated number between 0 and 1. The households are added to the synthetic pop-
ulation if the generated random number is less than selection probability.











nj = frequency of jth person-type in synthetic population
cj = IPF estimated constraint for jth person-type
A corresponding p-value is calculated with χ2 value and degree-of-freedom (df) to check the
validity of synthetic population. A synthetic population is repeatedly drawn until a desired
p-value is achieved or maximum number of draws is reached.
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5.2 Assign risk factors
Agents are assigned CHD risk factors - cholesterol (HDL, LDL and total cholesterol), systolic
blood pressure and smoking status using NHANES (National Health and Nutrition Examination
Survey) data. Risk factors are stratified by age category (45 to 64), race/ethnicity (White Non-
Hispanic and Black Non-Hispanic), gender (Male, Female), educational attainment (Less than
high school, Some college or more) and risk factor strata (32 strata) which is defined based
on the combination of 4 risk factors (HDL, total cholesterol, systolic blood pressure, smoking
status) and hypertension treatment.
6 Input data
The model did not require input data beyond what was provided in initialization, since the
environment remained constant throughout the simulation.
7 Sub-models
The sub-models of each intervention scenario are described in detail below:
7.1 Compute 10-year risk of Fatal CHD before the intervention
In this sub-model, we compute agent’s 10-year risk of Fatal CHD (as described in section 8)
before we execute the intervention. The purpose of this step is to create a baseline for 10-year
Fatal CHD risk by race-gender (white non-Hispanic men, white non-Hispanic women, black
non-Hispanic men and black non-Hispanic women).
7.2 Execute intervention
In this step, we execute one (or combinations) of the following interventions:
7.2.1 Tobacco tax intervention
This intervention captures the change in agent’s smoking behavior after an increase in tobacco
taxes. A random number drawn between 0 and 1 is compared with probability of quitting smok-
ing tax intervention. If the random number generated is less than probability of quitting smok-
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ing, agent changes its smoking status from smoker to non-smoker. Risk factors are also re-
estimated after moving agents from high risk strata (strata with smoking as a risk factor) to low
risk strata (strata without smoking as a risk factor).
7.2.2 Statins intervention
This intervention determines whether an agent receives statins treatment to reduce his or her
cholesterol levels. Smokers with high total cholesterol, low HDL and high systolic blood pres-
sure are qualified for statins treatment. However, agents undergo statins treatment only if the
random number generated between 0 and 1 is less than probability of statins intake.
The change in cholesterol and triglycerides levels after statins treatment is calculated as shown
below:
LDL cholesterol:
LDL = LDL− pLDLChange× LDL (4)
HDL cholesterol:
HDL = HDL+ pHDLChange×HDL (5)
Triglycerides:
TG = TG− pTGChange× TG (6)
Total cholesterol:
TChols = LDL+HDL+ 0.2× TG (7)
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where,
LDL = LDL cholesterol
HDL = HDL cholesterol
TG = Triglycerides
Tchols = Total cholesterol
pLDLChange = percentage of LDL change after statins treatment
pHDLChange = percentage of HDL change after statins treatment
pTGChange = percentage of triglycerides change after statins treatment
7.2.3 Early education intervention
This intervention changes an agent’s education status. This behavior is exhibited by Black
Non-Hispanic agents in response to Improved Early Education (IEE) intervention. IEE works
on an assumption - it reduces education gap betweenWhite and Black Non-Hispanic agents and
increases the likelihood of Black Non-Hispanic agents to attend college if they are provided IEE
during their childhood.
This behavior is predicted based on the probability of attending college. If a random number
generated between 0 and 1 is less than probability of attending college, agents are assigned
education level of ”Some college or more”. The probability of attending college is calculated
by:
pCollege = (%WhiteNH(HE)−%BlackNH(HE))/%BlackNH(LE) (8)
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where,
White NH = White Non-Hispanic
Black NH = Black Non-Hispanic
HE = Some college or more
LE = Less than High School
7.3 Compute 10-year risk of CHD after the intervention
In this sub-model, we compute agent’s 10-year risk of CHD (as described in section 8) after
we execute the intervention. The purpose of this step is to analyze the effect of intervention on
10-year CHD risk among white-male, white-female, black-male and black-female.
7.4 Process CHD related deaths
In this step, we predict the number of CHD related deaths over the period of 10 years based on
SCORE equation as described in section 8.2. As CHD deaths can occur anytime between year 1
and year 10, it is randomly distributed by generating a random number between 1 and 10 (both
inclusive). The purpose of this sub-model is to account for Year of Life Lost (YLL) as result of
premature death due to CHD.
8 10-year risk of CHD (Coronary Heart Disease)
8.1 FHS (Framingham Heart Study) Hard CHD ATP-III Risk Equation
Framingham Heart Study has developed a mathematical function to predict the risk of CHD
(Coronary Heart Disease) events. It is a gender-specific multivariable equation consisting of
weighted CHD risk factors - age, total, LDL, HDL cholesterol, blood pressure, smoking and
diabetes status. Individual and mean of risk factors are plugged in the equation to calculate the
probability of developing CHD within a certain time period (eg. 10 years).
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The calculation of 10-year risk of Hard CHD using Framingham Risk Equation is shown below:
For male:
∑
βX = 52.009610× ln (Age) + 20.014077× ln (Tchols)− 0.905964× ln (HDL)
+ 1.305784× ln (SBP ) + 0.241549×Htn+ 12.096316× Smoker
− 4.605038× ln (Age)× ln (TChols)− 2.843670× ln (Age)× Smoker




βX = 31.764001× ln (Age) + 22.465206× ln (Tchols)− 1.187731× ln (HDL)
+ 2.552905× ln (SBP ) + 0.420251×Htn+ 13.075430× Smoker
− 5.060998× ln (Age)× ln (TChols)− 2.996945× ln (Age)× Smoker
(10)








Tchols = Total Cholesterol
HDL = HDL Cholesterol
SBP = Systolic Blood Pressure
Htn = 1 if an agent is under hypertension medication
= 0 otherwise
Smoker = 1 if an agent is a smoker
= 0 otherwise
X_indv = Individual risk factors
X_mean = Mean of risk factors
S_t = Average survival at t years
Equation 6 and 7 calculated the weighted sum of risk factors (both individual and mean of risk
factors). Equation 8 calculated probability of occurrence of CHD event in t years.
8.2 SCORE (Systematic Coronary Risk Evaluation) Risk Equation
The SCORE project developed risk charts to estimate ten-year risk of fatal CHD for high-risk
and low-risk European countries [3]. These risk charts were modeled as a function of age,
race-gender, cholesterol levels (Total or Total/HDL ratio), systolic blood pressure and smoking
status.
SCORE risk charts in equation form to predict fatal CHD are stratified by age, and race-gender
and can be represented as:




Probability = 1− Sexp (w)t (13)
where,
Tchols_indv = Agent’s total cholesterol level
Tchols_mean = Average total cholesterol in population
SBP_indv = Agent’s systolic blood pressure
SBP_mean = Average systolic blood pressure in population
Smoker = 1 if an agent is a smoker
= 0 otherwise
S_t = Average survival at t years
Equation 9 calculated the weighted sum of risk factors (total cholesterol, systolic blood pressure
and smoking status) and equation 10 estimated the probability of occurrence of fatal CHD in t
years.
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9 Years of Life Lost (YLLs)
YLLs refers to the number of additional years an individual would have lived without the dis-
ease.
This model uses SCORE’s predicted probabilities (Equation 10) from SCORE to predict the
death of an agent for computing Years of Life Lost (YLL). YLL, for each agent, can be calcu-
lated as:
Y LL = LE − AgeAtDeath
where,
YLL = Years of Life Lost
LE = Life Expectancy
AgeAtDeath = Age of an agent at death
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10 Summary of agent characteristics and initialization parameters











Less than high school














Life expectancy (High School or
less, Some college or more)
Value
White Male 72.0, 78.2
White Female 79.3, 82.8
Black Male 65.2, 72.3
Black Female 74.4, 77.9
10-year survival rate (Total CHD,
Fatal CHD)
Value
White Male 0.925, 0.990
White Female 0.971, 0.9968
Black Male 0.921, 0.9884
Black Female 0.954, 0.9941
Statins Intervention









Statins cost per year Value
Base case $ 76.14
Tobacco Tax Intervention
% change in smoking prevalence Value
White Male 0.4 ↓
White Female 0.6 ↓
Black Male 1.1 ↑
Black Female 1.2 ↓
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11 Model flow charts
1. Flow chart indicating steps in model initialization
Create synthetic population
using IPU method and
assign baseline attributes
(age, race, gender and
education) to agents









































Is age > 40





























1. Creating synthetic population
Algorithm 1 Synthetic population
1: procedure createPopulation()
2: compute selection probabilities for households (by type, size and income) using IPU
3: Import household-level PUMS dataset
4: for household type in PUMS households list do
5: num_household = household count by household type
6: while (num_household >0) do
7: random = rand(0, 1)
8: for id, probability in household type do
9: if (random <probability) then
10: household = households[id]
11: for person in household do
12: if (age >= 45 and age <65) then
13: if (race/ethnicity is White NH or Black NH) then
14: agent_type = agent type by age, race, gender and education










2. Assign CHD risk factors
Algorithm 2 CHD risk factors
1: procedure setRiskFactors()
2: agent_types = agent type by age, race, gender and education
3: nhanes_list_by_agent_type = (agent_type, (agents_per_strata, risk_strata, risk_factor))
4: for type in agent_types do
5: agents_by_type = agentList[type]
6: nhanes_list = nhanes_list_by_agent_type[type]
7: risk_strata = nhanes_list[0]->risk_strata
8: risk_factor = nhanes_list[0]->risk_factor
9: for agent in agents_by_type do
10: while (true) do
11: agents_per_strata = nhanes_list[0]->agents_per_strata




16: risk_strata = nhanes_list[0]->risk_strata




21: assign risk_strata and risk_factor to agent





1. Compute 10-year risk of CHD
Algorithm 3 10-year risk of CHD
1: procedure computeTenYearCHDRisk()
2: for agent in agent list do
3: pCHD_Framingham = compute using eq. 6, 7, 8
4: pCHD_Score = compute using eq. 9 and 10
5: end for
2. Statins intervention
Algorithm 4 Statins intervention
1: procedure statinIntake()
2: for agent in agent list do
3: if (age >40 and age <75) then
4: if (!statin and (LDL >130 or HDL <40 or high SBP or Smoker ) then
5: pStatinIntake = probability of statin intake
6: if (rand(0, 1) <pStatinIntake) then
7: LDL = LDL - LDL * (percentLDLchange/100)
8: HDL = HDL + HDL * (percentHDLchange/100)
9: TG = TG - TG * (percentTGchange/100)






3. Tobacco tax intervention
Algorithm 5 Tobacco tax intervention
1: procedure quitSmoking()
2: for agent in agent list do
3: if (agent is a smoker) then
4: pQuitSmoke = probability of quitting smoking
5: count = 0
6: if (rand(0, 1) <pQuitSmoke) then
7: old_risk_factor = risk_factor
8: smoking_status = false
9: update risk_strata
10: new_risk_factors_list = risk_factors[agent_type][risk_strata]
11: while (true) do
12: idx = rand(0, size of new_ risk_factors_list - 1)
13: new_risk_factor = new_risk_factors_list[idx]
14: if (new_risk_factor > old_risk_factor) then
15: if (count > 50) then
16: risk_factor = new_risk_factor
17: break
18: end if
19: count + +
20: continue
21: else








4. Early education intervention
Algorithm 6 Early education intervention
1: procedure attendCollege()
2: for agent in agent list do
3: if (Black NH and HS or less) then
4: pEducation = probability of attending college
5: if (rand(0, 1) <pEducation) then
6: education = some college or more
7: new_risk_factor_list = (pRisk, new_risk_factor)
8: for risk in new_risk_factor_list do
9: pRisk = risk->pRisk
10: if (rand(0, 1) <pRisk) then
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